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Abstract 
The University of Manchester 
Alexa Jeanes 
PhD in Cell Biology 
The Role of β1 integrins in the control of Mammary Epithelial Cell Proliferation 
August 2010 
 
The cell fate of proliferation is used as an end point for many studies, particularly in 
cancer research.  Primary mammary epithelial cells (MECs) are a common model in 
breast cancer research and MEC proliferation is limited to a few days which make it 
very difficult to study longer term.  I describe the establishment of a new culture 
system to allow the analysis of cultures of primary luminal MECs over many days. 
Culturing the cells in a 3D microenvironment directly following tissue extraction, 
isolating the 3D acini using PBS/EDTA and replating onto 2D surface to study 
proliferation, maintained the 3D in vivo proliferation potential of the cells. 
Manipulation of the cellular environment, using this novel method, can maintain the 
proliferative potential of primary MECs. Our data further reveals that the cellular 
environment has profound effects on the proliferative properties of the primary MECs 
and is dominant over growth factors. This novel methodology, to increase the 
proliferation window, will allow the use of MECs over a longer time period and was 
used to elucidate the mechanism by which β1 integrins regulate the proliferation in 
MECs. 
 
Integrins are required for cell cycle progression in epithelia, but the β-integrin 
subunits involved and the downstream mechanisms are not known. A CreERTM 
strategy was used to specifically delete the β1-integrin gene in situ from primary 
cultures of MECs. This resulted in a block of DNA synthesis. Despite the loss of β1-
integrins, no changes in cell shape, focal adhesion integrity or the ability of the cells 
to migrate were observed. In β1-integrin null cells, β3-integrin was expressed de 
novo, it associated with core adhesome components, and maintained focal adhesion 
signalling as determined by the presence of phospho-FAK and phospho-paxillin. β3-
integrin adhesions were unable to support Rac activation and nuclear translocation of 
ERK. This investigation reveals that β1-integrins are uniquely required for cell cycle 
progression in breast epithelia, but not for their migration. Thus, the control of 
epithelial cell fate is dependent on the signalling pathways that emanate from specific 
β-integrin mediated adhesions. 
Disorganised morphology, in addition to uncontrolled proliferation, is a typical feature 
of human breast cancer.  Associated with this aberrant morphology is a deregulation 
of integrin adhesion receptors.  We investigated the role of β1-integrin in the MCF10a 
breast cancer progression model; a series of increasingly transformed cell lines from 
a common genetic background.  The cell lines of the MCF10a progression series were 
grown in a 3D basement membrane culture, in which they formed complex 
disorganised multi-acinar structures, except the control normal MCF10a MEC cell line, 
which formed hollow acini.  Analysing β1-integrin expression using flow cytometry, 
showed similar surface expression levels, however confocal microscopy revealed 
different β1-integrin localisation in the malignant cell lines compared to the normal 
ones.  Treating the MCF10a progression panel cell lines with AIIB2, a β1 integrin 
inhibitory antibody resulted in the morphology of the treated 3D colonies becoming 
more compact, smaller, and similar to the MCF10a normal cells.   
 
All in all, the results presented in this thesis show the critical importance of integrins 
in regulating proliferation in MECs, the mechanism by which integrins exert this 
control and the role that this may have in breast cancer tumourigenesis. 
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1. Overall Introduction 
Cell adhesion is essential for the regulation of many aspects of cell behaviour, such 
as proliferation, migration and survival and therefore plays a critical role in 
embryonic development, tissue morphogenesis, homeostasis and disease.  Cell–cell 
adhesion and cell-ECM adhesion are mediated by various classes of cell surface 
adhesion receptors; cadherins, integrins, and members of immunoglobulin and 
selectin receptor families (Berrier and Yamada, 2007; Gumbiner, 2005).  
Integrins are a family of transmembrane glycoproteins that primarily mediate cellular 
adhesion to the extracellular matrix (ECM), and provide a link to the cytoskeleton 
inside the cell.  They also act as highly regulated signalling molecules which function 
by coordinating the formation of signalling platforms (adhesomes) that transduce 
signals from the ECM into the cell and also direct cell polarity and differentiation 
(Hynes, 1992; Hynes, 2002; Zaidel-Bar et al., 2007). 
The importance of cellular adhesion to the ECM by integrins has been demonstrated 
by genetic approaches and integrins are deregulated in a huge variety of diseases, 
contributing to the pathogenesis.  Changes in integrin expression, activation and 
localisation are central to many diseases such as cancer, autoimmunity and 
inflammatory diseases. Inherited disorders, such as glanzmann's thrombasthenia, 
contain mutations in integrin genes and lead to defects in wound healing and blood 
clotting (Lal et al., 2009; McCarty, 2009; Rathinam and Alahari, 2010; Schultz and 
Wysocki, 2009).  As the importance of integrins has become apparent in recent 
years, there has been a focus on the development of integrin antagonists as possible 
avenues for future therapies of this wide spectrum of diseases (Bosserhoff, 2006; 
Staunton et al., 2006). 
In this literature review, I will give an overview of integrin structure, function and 
signalling capabilities, focussing on their critical regulation of cell cycle.  I will then 
discuss the role of integrins in the mammary gland and what is known about 
integrins in breast cancer development, progression and pathogenesis.  
2. Integrin Adhesion Receptors 
Integrins are heterodimeric transmembrane glycoproteins that have key roles in 
mediating cell-ECM and cell-cell interactions. Their expression is restricted 
eukaryotes and multicellular organisms, from sponges to c.elegans to humans.  
There are no equivalent homologs in prokaryotes and fungi (Hynes and Zhao, 2000). 
Integrins serve as a mechanical link from extracellular contacts to the cytoskeleton 
inside the cell, and also serves as docking platform for a myriad of adapters and 
signalling enzymes.  This platform functions to provide framework for cells to sense 
16 
 
and respond appropriately to their microenvironment, organise their shape and 
establish stem cell niches (Tanentzapf et al., 2007). Integrins also activate many cell 
signalling pathways, thus making them important molecules in many cellular 
processes (Harburger and Calderwood, 2009; Hynes, 2002). 
2.1 Integrin Structure 
Integrin receptors are composed of an alpha (α) and a beta (β) subunit that are held 
together by non-covalent bonds to form the active heterodimer (Figure 1a). 18 
different α subunits (120-180kDa) and 8 β subunits (90-110kDa) have been 
identified in the mouse and human genomes (Barczyk et al., 2010).  Of the 100 
possible heterodimers, only 24 distinct functionally active heterodimers have been 
identified in vivo (Figure 2) (Takada et al., 2007).  Most β subunits have a short 
cytoplasmic tail, although the β4 subunit has a cytoplasmic domain of approximately 
1000 amino acids (Humphries, 2000b).  The integrin family is further diversified by 
alternative splicing of some α and β subunits, and post-translational modifications, 
such as disulphide bonds and glycosylation (Bellis, 2004; Gu et al., 2009; Zhao et al., 
2008).  
2.2 Integrin Ligand and Affinity 
Integrin heterodimers are low affinity receptors that bind a variety of ECM proteins 
including fibronectin, laminin and collagen or counter receptors of the 
immunoglobulin superfamily (Humphries et al., 2006).  Ligand specificity is 
determined by heterodimer composition and cellular context.  While some integrin 
heterodimers recognise a single ligand for example α5β1 binds only fibronectin, 
others bind several ECM proteins.  Integrins such as αvβ3 recognise the tripeptide 
sequence Arg-Gly-Asp (RGD) found on many ECM proteins such as vitronectin, 
fibronectin and collagen (Figure 2).   Divalent cations are essential to integrin activity 
as they cause a conformational change leading to the exposure of the ligand binding 
site in the α and β subunits (Mould et al., 1998).  The acidic aspartate or glutamate 
amino acid residues present in the integrin binding site in ECM proteins provides an 
additional coordination site for the cation in the binding pocket ensuring high affinity 
ligand binding (Lee et al., 1995).  The binding of integrin heterodimers to ECM 
proteins is further increased by clustering and the recruitment of accessory proteins, 
such as talin and by conformational change (Figure 1b) (Askari et al., 2009; Stupack 
and Cheresh, 2002). However, the relative contributions of these different actions 
vary depending on the integrin, cell type and biological circumstances. 
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a) A schematic diagram of the activated ligand bound form of an integrin heterodimer.  The 
 subunit comprises an N-terminal -propeller, followed by three -sandwich domains 
(Thigh, calf1 and calf2) and a short C-terminal cytoplasmic tail. The -subunit comprises an 
N-terminal PSI domain, followed by a -sandwich hybrid domain, an A-domain, four EGF-
like repeats, a -tail domain and a longer C-terminal cytoplasmic tail which binds focal 
adhesion proteins such as talin.   
b) Integrins exist in a bent inactive conformation with the ‘head’ domain facing the plasma 
membrane and a low ligand affinity.  Upon ligand binding, the two ‘leg-pieces’ of the 
integrin heterodimer move apart, breaking the salt bridge present and resulting in the fully 
active, extended integrin conformation (Mould and Humphries, 2004).  This enables the 
recruitment of a number of focal adhesion proteins which include Focal Adhesion Kinase 
(FAK), paxillin, talin and Integrin Linked Kinase (ILK) that bind to the NPXY and HDRK 
motifs that are revealed.  These proteins function to link integrins to the actin cytoskeleton 
and downstream signalling pathways.  
Figure 1: Integrin Heterodimer 
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The composition of integrin heterodimers determines ligand binding specificity.  It 
can be broadly classified into subfamilies.  The specificity of the β subunit depends 
on the partnering α subunit. The dimers shown are present in the mammary gland 
and the lines in bold represent dimers that are directly relevant to this project.  
Figure 2: Integrin Dimers and Ligands 
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 As integrins bind to the ECM, they become clustered together in large numbers due 
to the multivalent nature of the ECM protein ligand (Koo et al., 2002).  The formation 
of this complex recruits a range of intracellular proteins such as kinases, non-
enzymatic adapter proteins and GTPases.  Association with the cytoskeleton 
promotes the assembly of actin filaments, completing the formation of a large protein 
complex called a focal adhesion.  The increased adhesion as a result integrin 
clustering is further enhanced by a conformational change and ‘integrin activation’ 
(Giancotti and Ruoslahti, 1999; Shattil et al., 2010) (Figure 1b). The ‘inside-out’ 
signals that stimulate this conformational change will be discussed below.  
2.3 Integrin expression and in vivo functions 
Integrins are widely expressed throughout multi cellular organisms with every cell 
possessing its own integrin signature. They perform different roles in different tissues 
that are determined by the heterodimers composition and expression.  For example 
β4 integrin heterodimers form hemidesmosome adhesions with intermediate 
filaments in epithelial tissues that are critical for tissue strength and structural 
integrity (Borradori and Sonnenberg, 1999).  This integrin signature has been used 
as a marker for progenitor stem cells and cancer stem cells (Pontier and Muller, 
2009; Vaillant et al., 2008).  For example cells with high levels of β1 and α6 integrins 
as well as low levels of an epithelial marker CD24 were able to regenerate an entire 
mammary gland and have been characterised as mammary stem cells (Shackleton et 
al., 2006; Stingl et al., 2006). 
Integrins have a large variety of the functional roles in vivo that have been 
demonstrated over the past 10 years by the generation of integrin knockout 
transgenic mice.  The loss of almost any integrin α- or β- subunit leads to biological 
defects that range in phenotype from embryonic lethality to subtle imperfections, 
such as reduced immune responses or mild cartilage, angiogenesis or wound healing 
defects, in an otherwise viable and fertile mouse (Barczyk et al., 2010; van der Flier 
and Sonnenberg, 2001).  As the integrin β subunits often pairs with a variety of α 
subunits, if the β subunit is absent, all the heterodimers that usually form are not 
present, resulting in the more severe phenotype. For example the β1 KO mouse was 
embryonic lethal at day 6.5 (Brakebusch et al., 1997) and the β4 KO mouse showed 
peri-natal lethality (Fuchs et al., 1997).    There are only minor defects in many α 
subunit integrin KO mice, such as  the α2 KO, that has abnormal haemostasis and 
defective branching morphogenesis in the mammary gland (Chen et al., 2002). This 
suggests that integrins are part of a complex integrated signalling network where 
other receptors and integrin subunits compensate in the absence of a particular 
integrin subunit and demonstrates some redundancy as multiple integrin 
heterodimers can bind one ligand (Schwartz and Ginsberg, 2002). 
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3. Integrin Signalling 
Integrins do not simply act as anchors to attach cells to their environment.  The 
adhesion through integrins dynamically mediates many cell fate decisions, such as 
proliferation, differentiation, migration and survival.  This is further regulated by 
cooperation with other cell surface proteins, such as growth factor receptors, 
cytokine receptors and syndecans (Streuli and Akhtar, 2009). 
Integrin signalling is bi-directional, which means its activity is regulated from both 
inside and outside of the cell, with different biological outcomes (Ginsberg et al., 
2005). Both these integrin signalling mechanisms will be described, but the overall 
focus will be on ‘outside in’ signalling. 
3.1 Integrin Activation or ‘inside out’ signalling 
Integrins can regulate their own ligand binding activities on the cell surface via 
signalling pathways from within the cell and this is called ‘inside out’ signalling 
(Gahmberg et al., 2009).  This process was initially characterised in haematopoetic 
cells such as platelets and leukocytes but has been shown to occur in other cell types 
(Mould and Humphries, 2004).  
In some cells, integrins are expressed on the cell surface in an inactive folded 
conformation in which the ligand binding sites are adjacent to the membrane 
resulting in a low affinity binding state.  Integrins are converted to their active 
straightened ‘high affinity’ state by intracellular signals which stimulate the integrins 
to undergo a conformational change, though the exact structural changes that occur 
are controversial (Humphries, 2000a) (Figure 1b).  Binding of the extracellular ligand 
further stabilises this active conformation.  However recent evidence has shown that 
integrins have many conformational states that enable fine adjustment of integrin 
function as a result of regulation by ligand binding and intracellular signals (Askari et 
al., 2009; Mould and Humphries, 2004).  The binding of the cytoskeletal adapter 
proteins, talin and kindlin, to the β subunits tail via the NPXY and NXXY motifs 
respectively, are two such intracellular signals that stimulate the conformational 
change to the active ligand binding state (Larjava et al., 2008; Ma et al., 2008; 
Tadokoro et al., 2003).  FAK and ILK, the focal adhesion signalling enzymes, which 
are usually restricted to recruitment to integrin tails by outside in signalling, have 
been found to also affect integrin activation via inside out signalling (Honda et al., 
2009; Michael et al., 2009). 
After conformational activation, integrin clustering and aggregation in the plane of 
the membrane occurs, forming focal complexes and further enhancing the ligand 
affinity. Integrin clustering is controlled by many events. The close proximity of the 
multiple integrin binding sites in the ECM induces integrins to localise together to 
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bind the ECM protein (Koo et al., 2002).  Localisation of a number of integrin 
heterodimers in cholesterol rich micro-membrane domains known as lipid rafts 
further facilitates clustering and is enhanced by association with tetraspanin proteins 
(Echarri et al., 2007; Hemler, 2005). Integrin clustering and the formation of focal 
adhesions is further modulated though the recruitment of intracellular proteins to the 
intracellular integrin tails.  The cytoskeletal adapter protein talin is critical in integrin 
activation and clustering. Talin is an antiparallel homodimer consisting of a head and 
a rod domain (Calderwood, 2004).  The talin head contains a FERM domain that binds 
to the NPXY motif in the PTB domain of β integrin tails inducing conformational 
change and integrin activation (Calderwood et al., 2002). Due to the homodimeric 
nature of talin, the head domains on different dimerised molecule can bind to 
multiple β subunits inducing integrin clustering (Tadokoro et al., 2003). The 
phosphorylation of integrin cytoplasmic tails can further modulate adhesion, for 
example phosphorylation of Tyr747 on β3 integrin was required for αvβ3 modulated 
adhesion (Blystone et al., 1997).  The GTP-GDP exchange of GTPases was also found 
to be critical for the activation of integrin αIIbβ3 in platelets, whereby  integrin 
activation was dependent on the recruitment and activation of  the GTPase Rap1 by 
talin (Han et al., 2006).   
The clustering of integrins facilitates multivalent binding with the ligand, promoting a 
stronger attachment.  It also promotes the recruitment of numerous intracellular 
proteins to the focal complex leading to the formation of focal adhesions (Geiger et 
al., 2009) (Figure 3).     
3.2 ‘Outside in’ Signalling 
The other paradigm in integrin signalling is the stimulation of intracellular pathways 
by extracellular binding to the ECM, also called ‘outside in’ signalling (Ginsberg, 
Partridge et al. 2005).  The signalling pathways modulated by integrins are involved 
in cell survival, proliferation and migration and it is this type of integrin signalling 
that I will focus on.   
Since integrins are not enzymes, they rely on the association with adapter proteins 
and enzymes for their signalling activity.  Integrins, adapter proteins and signalling 
enzymes associate with cytoskeletal proteins in large multi-protein signalling 
complexes termed focal adhesions (Figure 3).  Some proteins such as tensin, 
vinculin, talin and α-actinin bind both integrins and actin thereby linking the ECM with 
the cytoskeleton (Wiesner et al., 2005).  Adapter proteins such as Grb2, Shc, 
p130Cas, paxillin and kindlins link focal adhesions with intracellular signalling 
pathways via kinases such as Focal Adhesion Kinase (FAK), the Src family of tyrosine 
kinases (SFKs),  Integrin Linked Kinase (ILK)  and Rho family GTPases (Geiger et al., 
2009).  Integrins also interact with other cell surface receptors such as receptor 
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tyrosine kinases (RTK) further modulating the signalling events, in a process called 
receptor crosstalk (Streuli and Akhtar, 2009).    
3.2.1 Integrins and the cytoskeleton 
Integrins provide the mechanical link from the ECM to the actin cytoskeleton inside 
the cell.  The integrin-actin connection is important for cellular processes involving 
cell shape and movement, such as cell migration and morphology and polarity.  The 
connection is highly dynamic and the cytoskeleton is undergoes constant remodelling 
(Brakebusch and Fassler, 2003). Many proteins in focal adhesions either directly link 
integrins to actin filaments, such as talin, α-actinin and filamin, which act as 
structural adapters or Rho GTPases, such as RhoA and Rac1, that are involved in the 
dynamic regulation of the actin itself (DeMali et al., 2003). 
The Rho GTPases, Cdc42 and Rac1, are recruited to focal complexes on initial 
attachment to the ECM and are activated by the exchange of GDP to GTP facilitated 
by guanine nucleotide exchange factors (GEFs), possibly Vav1 (Miranti et al., 1998).  
Activated Cdc42 and Rac leads to actin polymerisation.  RhoA is activated on the 
maturation of focal complexes to focal adhesions and leads to the increase in tension 
and increased contractility at integrin ligation sites, that can lead to cell migration 
(Burridge and Wennerberg, 2004).   
The majority of integrin heterodimers form transmembrane links to the actin 
cytoskeleton.  The α6β4 integrin heterodimer, however, associates with keratin 
intermediate filaments and other proteins to form a hemidesmosome complex which 
is a separate class of adhesive structure primarily found in the epidermis.  This will 
not be covered in this section as I will focus on the actin based mechanisms of 
integrin regulation of the cytoskeleton. 
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Integrins bound to the ECM cluster together and form an adhesion structure 
known as a focal adhesion.  Many different proteins are recruited to focal 
adhesions such as adapter proteins (p130Cas, talin, Grb2), GTPases (Ras), 
kinases (FAK, ILK and Src) and actin binding proteins (paxillin, α-actinin, vinculin, 
α-parvin, PINCH and filamin).  Together they connect the ECM to the actin 
cytoskeleton and also provide an important signalling platform involved in many 
cellular processes such as proliferation and survival. 
Figure 3: Schematic Representation of Key Signalling 
Interactions in a Focal Adhesion Site 
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There are four main proteins that link integrins to the actin cytoskeleton; talin, 
filamin, α-actinin and ILK (Figure 3).  Talin can bind actin directly or through the 
cytoskeletal protein vinculin, that can induce actin polymerisation by recruitment of 
the nucleation complex Arp2/3 (DeMali et al., 2002).  α-actinin also binds to vinculin 
as well as cross linking actin into actin bundles.  It interacts with many other 
signalling proteins such as MEKK and the p85 subunit of phosphatidylinositol-3-
kinase (PI3K) indicating that it also functions as a signalling scaffold protein 
(Christerson et al., 1999).  Another cytoskeletal protein that binds both actin and 
integrins is filamin.  In vitro, filamin interacts with Rho GTPases, MEKK and GEFs as 
well as integrins and actin, but the functional implications of this has yet to be 
characterised (Brakebusch and Fassler, 2003).   
The final actin-integrin linking protein is ILK acting as part of the ILK-PINCH-parvin 
(IPP) complex.  This heterotrimeric complex functions both as an adapter between 
integrins and the actin cytoskeleton, but also as a signalling hub (Legate et al., 
2006).  IPP is assembles in the cytosol prior to cell adhesion and is recruited to focal 
adhesions via paxillin and kindlin-2 (Nikolopoulos and Turner, 2001; Zhang et al., 
2002b).  Both α- and β-parvin binds to the actin cytoskeleton directly and also 
through a range of binding partners such as α-actinin and the GEF α-Pix, therefore 
suggesting its role in both the regulation of actin dynamics itself and the regulation of 
GTPases Rac and Cdc42 (Rosenberger et al., 2003). 
As demonstrated, many of the proteins that are important in the regulation of the 
actin cytoskeleton play a dual role in focal adhesions. They attach to other signalling 
proteins and function as platforms, bringing together the components required for 
downstream signalling for cellular processes such as proliferation.  Focal adhesions 
bring the signalling pathways stimulated by integrins into close proximity therefore 
they co-operate and act together to result in the desired cellular functional outcome.  
Particularly important components of the focal adhesion complex that are required for 
modulating signalling pathways are the integrin signalling enzymes, FAK, ILK and 
Src. 
3.2.1 Integrin signalling enzymes 
The non-receptor tyrosine kinase, FAK is a key mediator of integrin signalling.  FAK is 
recruited to focal adhesions by the conformational activation of integrins whereby the 
separation of the integrin cytoplasmic tails in the ‘active’ conformation reveals the 
key binding sites enabling localisation of FAK to integrins (Mitra and Schlaepfer, 
2006; Parsons, 2003).  FAK binds to the membrane-proximal HDRK motif on the 
cytoplasmic tails of the β integrin subunit either directly via its focal adhesion 
targeting (FAT) domain or indirectly via integrin-associated proteins, such as paxillin 
and talin (Schaller et al., 1995).  FAK recruitment results in Y397 
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autophosphorylation, creating a high affinity Src homology(SH) 2 binding site for Src 
(Schaller et al., 1994).   
Upon binding to pY397, Src is activated and subsequently further phosphorylates key 
tyrosine residues on both FAK  (Y576 and Y577) and other adapter molecules such as 
paxillin (Schaller and Parsons, 1995), which generates binding sites for SH2-domain 
proteins and initiates a variety of intracellular signalling cascades. For example, 
Phosphoinositide-3-kinase (PI3K) which is a critical regulator of cell survival binds to 
Y397 (Chen et al., 1996).   Shc and Grb2 bind to Y397 and Y925 respectively 
controlling cell proliferation though the MAPK module with FAK therefore functioning 
as a scaffold (Schlaepfer et al., 1994). SH3 containing proteins such as p130Cas can 
also bind to FAK on its central proline rich regions (Polte and Hanks, 1995)(Figure 4).  
The interaction between p130Cas and FAK has been demonstrated to play a critical 
role in the regulation of cell migration (Cary et al., 1998).  However, cellular 
embryonic lineage is important in the recruitment of different signalling proteins to 
FAK as it was shown that epithelial cells require FAK and paxillin signalling for cell 
survival whereas fibroblasts are dependent on the association between FAK and 
p130Cas (Zouq et al., 2009).  This demonstrates that the particular cellular function 
of FAK is often dependent on the specific cell type and proteins recruited. 
Src is the principle member of the Src Family Kinases (SFKs) which also include Fyn, 
Lyn and Yes. SFK’s are membrane localised due to N-terminal myristylation and 
contain a proline rich binding domain (SH3), a SH2 phosphotyrosine binding domain 
and a catalytic kinase domain (Figure 4). Autophosphorylation at Y416 in the kinase 
domain leads to enhanced kinase activity whereas phosphorylation by Src-kinase 
(Csk) on Y527 leads to inactivation due to the formation of intramolecular 
interactions (Abram and Courtneidge, 2000). Src is recruited to the focal adhesion 
signalling complex upon integrin activation by binding to Y397 on FAK and 
subsequently phosphorylates a number of other focal adhesion proteins as well as 
FAK including vinculin, talin, paxillin, tensin, ezrin and p130Cas (Mitra and 
Schlaepfer, 2006). Other known targets of Src are enzymes involved in phospholipid 
metabolism, such as PLC-γ , p85 subunit of PI3K and the signalling molecules 
p190RhoGAP and p120rasGAP (Abram and Courtneidge, 2000).  SFKs can also 
directly phosphorylate β integrin subunits on the tyrosine residues of the NPXY motif 
further modulating integrin activity and facilitating the recruitment of proteins to the 
PTB domain (Law et al., 1996) (Mainiero et al., 1995).  Phosphorylation of β1 integrin 
in response to Src transformation has been demonstrated and the integrin 
phosphorylation directly contributed the transformation phenotypes (Sakai et al., 
2001).  
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a) FAK is composed of a central catalytic domain flanked by large domains that contain 
binding sites for a number of different signalling and adapter proteins.  Within the focal 
adhesion targeting (FAT) domain there are a number of binding sites for focal adhesion 
proteins such as paxillin and talin, thereby linking FAK to integrins.  When phosphorylated, 
Y397 creates a binding site for SH2 containing proteins such as the p85 subunit of in PI3K, 
Src and the adapter protein Shc linking it to both survival and MAPK pathways.  The 
adapter protein p130Cas binds the proline rich region though its SH3 domain and can 
activate a migration pathway 
b) Src has an N-terminal sequence that directs membrane localisation through myristylation 
and palmitoylation and a SH3 domain that binds directly to polyproline rich sequences.  The 
SH2 domain binds to phosphotyrosine residues such as pY397 of FAK (a). The activity of 
the kinase domain is regulated by phosphorylation of two tyrosine residues, Y416 in the 
kinase domain and Y527 in the C-terminal tail.  Autophosphorylation of Y416 results in 
increased kinase activity whereas phosphorylation of Y527 stabilises an intramolecular 
interaction that represses the kinase activity.  Dephosphorylation of Y527 can therefore 
activate Src.  
Figure 4: Schematic Representation of FAK and Src and their 
interacting proteins 
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Another key integrin signalling enzyme is Integrin Linked Kinase (ILK). Contrary to its 
name, ILK does not have any intrinsic kinase activity, but can be described as a 
pseudokinase.  Pseudokinases are catalytically inactive remnants of an active kinase 
that uses its substrate recognition motif to interact with other proteins (Wickstrom et 
al., 2010).  ILK therefore functions as a scaffold, binding directly to the cytoplasmic 
tails of β subunits of a variety of integrin heterodimers and is also recruited to the 
integrin β subunits by kindlins (Ussar et al., 2006). The majority of ILK functions 
occur when bound to the adapter proteins particularly interesting Cys-His rich protein 
(PINCH) and parvin forming a heterotrimeric complex known as the IPP complex 
(Legate et al., 2006).   ILK and the IPP complex have many effects downstream of 
integrin signalling, primarily in cytoskeletal reorganisation that is important in cell 
polarisation and morphogenesis.  
As demonstrated, many of the signalling proteins in focal adhesions play a dual role. 
These proteins, not only have their own catalytic activity, but function as platforms, 
bringing together the components required for downstream signalling to regulate 
cellular processes.  Focal adhesions bring into close proximity the signalling 
molecules stimulated by integrins therefore they co-operate and act together to 
result in the desired cellular functional outcome.  One particularly important cell fate 
that is regulated by integrins, cooperating with other signalling pathways, is 
proliferation.  This tight regulation is often altered and can lead to and contribute to 
the pathogenesis of diseases such as cancer, therefore this literature review will now 
focus on the role that integrins have in the regulation of cell cycle and proliferation. 
3.3 Integrin Signalling in Proliferation and Cell Cycle Control 
Most normal non-transformed cells require attachment to the ECM to undergo cell 
proliferation; this is often called anchorage dependence.  Integrins impart controls at 
various stages of the cell cycle; from extracellular signals through growth factors 
(GF), through early cell cycle at G1/S and late stages such as the G2/M checkpoint 
and cytokinesis. For example, β1 integrin knock out in vivo studies in chondrocytes, 
skin, hair follicle and mammary gland all showed a cell cycle block, therefore 
suggesting a critical role for integrins, and β1 integrin in particular, in proliferation 
regulation (Aszodi et al., 2003; Brakebusch et al., 2000; Li et al., 2005; Raghavan et 
al., 2000).   
3.3.1 Cooperation with Growth Factors 
Growth factor (GF) activation is not sufficient to stimulate progression through the 
cell cycle; it requires integrin-mediated ligation to the ECM, that acts as an 
environmental and spatial checkpoint (Streuli, 2009).  Extracellular GFs bind to GF 
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receptors and provide the signals for the initiation of the cell cycle, by activation of 
signalling pathways such as the ERK/MAPK pathway, which results in the 
transcription of the cell cycle machinery such as cyclins. However, the cell cycle is 
only able to proceed only if the cell is in the correct environment and receiving the 
correct signals via integrins and the ECM.  Integrins therefore act as a context control 
mechanism (Katz and Streuli, 2006; Streuli and Akhtar, 2009)(Figure 5).   
The interaction between GF receptors and integrins is both a physical and a proximal 
one.  They associate in macromolecular signalling complexes and act in a synergistic 
manner to ensure an optimal response.  (Yamada and Even-Ram, 2002)(Figure 6).  
However, integrins can cause ligand independent activation of GF receptors.  For 
example, platelet derived growth factor receptor (PDGFR) and EGFR can be 
stimulated purely by adhesion to the ECM, in the absence of growth factors 
(Miyamoto et al., 1996; Moro et al., 1998). Further to this, the interaction between 
GF receptors and integrins appear to be integrin subunits specific whereby c-Met 
(Hepatocyte GF receptor) and the EGF receptor, ErbB2, associate with α6β4 
(Trusolino et al., 2001).  This has also been shown in some epithelial cells, where 
integrin adhesion caused activation of the EGF receptor, in the absence of EGF by 
ShcA phosphorylation.  Some of the EGF receptors formed a complex with β1 integrin 
and subsequently recruited a variety of proteins such as Src and p130Cas to 
stimulate ERK and Akt pathways, cyclin D synthesis and progression through G1/S 
(Bill et al., 2004).  
Activation of GFR such as EGFR by extracellular ligands such as EGF leads to initiation 
of the ERK/MAPK signalling cascade.  This can occur in suspension as well as in 
attached cells, however for the ERK activation to be translated into cell cycle entry, 
the cells must be attached and therefore be receiving signals from the ECM via 
integrins (Assoian and Schwartz, 2001). Both ECM adhesion and GFs are required for 
sustained and synergistic ERK signalling, leading to optimal signalling, 
phosphorylation of target genes such as Elk-1 in the nucleus, subsequent cyclin D1 
expression and cell cycle entry (Walker and Assoian, 2005).  
Integrins also fine tune GF receptor induced cellular responses by recruiting specific 
adaptor proteins.  For example, in Mouse Embryonic Fibroblasts (MEFs), adhesion to 
fibronectin promotes the association of SHP-2 with the PDGFRβ.  SHP-2 
dephosphorylates the tyrosine residue that would usually bind RasGAP, therefore 
increasing Ras and ERK stimulation and cell cycle entry (Eminaga and Bennett, 
2008).  
Integrins and GF receptors therefore act together to become joint sensing apparatus 
that enables cells to detect their environment and respond to the extracellular signals 
to determine whether or not they should proliferate. 
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3.3.2 Control at G1/S 
Sustained ERK activity is required for the induction of the cyclin D1 gene and the 
subsequent transcription of genes required for S phase (Figure 6) (Assoian and 
Schwartz, 2001; Walker and Assoian, 2005).  
Integrin-dependent signalling pathways regulate ERK activity by acting both up- and 
downstream of the GTPase Ras in the ERK/MAPK pathway (Figure 7).  Upstream, 
integrins can directly stimulate the MAPK pathway by coupling to the kinases FAK and 
Src (through the β subunit) or to caveolin/ Fyn/Shc (through the α subunit).  In both 
cases, the adapter protein Grb2 is recruited to the membrane, where it stimulates 
the activity of the Ras  (Schlaepfer et al., 1994).  Another adapter protein, p130Cas, 
is also activated by FAK (Schlaepfer et al., 1997), and stimulates the GTPase Rap1 
and MAPKKK B-Raf (Barberis et al., 2000), thereby linking it to the MAPK pathway via 
another mechanism.   
Both mechanisms result in the transcriptional activation of the cyclin D1 promoter, 
therefore demonstrating the ability of integrins through FAK to regulate cyclin D1 
expression (Figure 7) (Zhao et al., 2001). 
Signalling through PI3K and its effectors such as Protein Kinase B (PKB)/Akt, as a 
result of activation by either FAK or ILK, also contributes to cyclin D1 expression 
(Treinies et al., 1999).  PI3K also regulates cyclin D1 stability and localisation by the 
inactivation of glycogen synthase kinase-3β (GSK-3β).  Cyclin D1 is exported from 
the nucleus and proteolytically degraded when GSK-3β is active, thus the inactivation 
of GSK-3β results in increased levels of nuclear cyclin D1 (Figure 7) (Diehl et al., 
1998). 
Integrins can also influence the cell cycle through the Rho GTPases, Rac1 and Cdc42 
(Figure 6) (Figure 7) (Welsh, 2004; Welsh and Assoian, 2000).  Rac stimulates p21 
activated kinases (PAKs) which phosphorylates Raf and MEK, increasing their activity 
(Slack-Davis et al., 2003) (Figure 7).  Integrin mediated Rac activation has also been 
shown to be required for the nuclear translocation of ERK where it activates the 
transcription factor Elk-1 and thereby cyclin D expression (Aplin et al., 2001) (Hirsch 
et al., 2002).   
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The cell cycle is a series of tightly controlled events that drive the replication of 
DNA and cell division. It can be divided into four phases; DNA synthesis (S), 
nuclear division (M = mitosis), and two regulatory gap phases (G1 and G2).  The 
transition from G1 to S phase is regulated by cell adhesion and growth factors.  
The restriction point (R) signifies the end of the cycle’s dependence on 
extracellular stimuli and is the point of no return. A cell can exit the cell cycle and 
enter a state called quiescence (G0) where it both pauses and can re-enter the cell 
cycle under the correct conditions or the cell undergoes terminal differentiation or 
cell death. The stages labelled in red are dependent on full integrin function for 
correct execution. 
The cell cycle is driven by a class of constitutively expressed nuclear enzymes 
called cyclin-dependent kinases (CDKs).  The activity of these kinases is regulated 
by the presence of their cyclin partners and it is the temporal translation of 
different cyclins at different stages of the cell cycle that regulates Cdk kinase 
activity.  The kinase activity of CDKs drives the cell cycle as phosphorylation 
Figure 5: The Cell Cycle 
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Integrins and growth factor receptors (GFRs) act together to ensure correct 
regulation of the cell cycle and proliferation.  Signalling through the ERK/MAPK 
phosphorylation cascade requires input from cell adhesion through integrins and 
from growth factors.  This results in the phosphorylation and activation of the 
transcription factor Elk-1 and subsequent transcription of cyclin D1. Cyclin D1 
binds Cdk4/6 and along with Cyclin E-Cdk2 phosphorylates the retinoblastoma 
protein (Rb).  Rb forms a complex with members of the E2F transcription factor 
family, directly blocking their activity.  Upon phosphorylation of Rb, E2Fs are 
released and can stimulate gene expression of genes required for DNA replication 
and progression through S phase such as cyclin A.  Phosphorylation of Rb is an 
event that signifies the end of the cells dependence on extracellular stimuli for 
progression through the cell cycle, and is termed the restriction point (R) (Figure 
5).  Integrins stimulate the degradation pathways through the Rho family proteins 
RhoA, Rac1 and cdc42, which down-regulate the CDK inhibitors p21Cip1 and p27Kip1 
,thus allowing activation of the cyclin E-CDK2 complex.   
Figure 6: Co-operative Signalling Between Integrins and 
Growth Factor Receptors in Cell Cycle Control.  
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Integrins stimulate the activation of ERK through multiple transduction pathways. 
Upstream of Ras, ERK can be activated by FAK/Src linking to Grb2 and 
caveolin/fyn.  FAK also signals through p130Cas, Rap1 and B-Raf to activate MEK.  
Rac acts at many points in the MAPK pathway either directly for example ERK 
nuclear translocation or through PAK.  PI3K is activated by FAK and acts to 
stabilise cyclin D1 in the nucleus by inhibition of GSK-3β. Many of these pathways 
work in co-operation with growth factor RTKs (not shown).  
Figure 7: Integrin Dependent Signalling Pathways Regulating 
ERK Activity and Cyclin D Expression and Activity. 
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Cell adhesion induced integrin-signalling also down-regulates the CDK inhibitors 
(CKI) p21cip1 and p27kip1 in mid-late G1 (Figure 6).  The down-regulation of these 
CKI’s is a direct consequence of cellular adhesion, as cells in suspension are often 
found to have high levels of p21cip1 and p27kip1 and attachment to the ECM induces 
their proteasomal degradation (Bao et al., 2002).  In attached cells, integrins via 
RhoA activate the cyclin E-CDK2 complex which phosphorylates p27kip1, targeting it 
for ubiquitination and subsequent degradation (Hu et al., 1999).  The ubiquitin ligase 
Skp2, part of the SKP1-CUL1-F-box protein (SCF) E3 ubiquitin ligase complex, is 
activated by adhesion to the ECM and, thus, directly induces p27kip1 proteasomal 
proteolysis (Carrano et al., 1999). 
The activity of the other CKI, p21cip1, is also tightly regulated by integrins at many 
levels.  As a result of the up-regulation of cyclin D1, there is increased formation of 
cyclin D1-Cdk4/6, which sequesters p21cip1 away from the cyclin E-Cdk2 complexes. 
This increases the activity of the cyclin E-Cdk2 complexes and phosphorylation of Rb 
(Roovers and Assoian, 2000).  In normal cells, p21cip1 is induced rapidly through the 
ERK pathway upon mitogen stimulation during early G1 and then subsequently down-
regulated with the integrin-mediated activation of cyclin E-Cdk2 in late G1 (Assoian 
and Schwartz, 2001). The downregulation of p21cip1 by proteasomal degradation, 
though the SCF E3 ubiquitin ligase complex, is suggested to be through integrin 
induced Rac1/cdc42 signalling (Bao et al., 2002).  Therefore if the cell is not 
receiving the correct signals from the ECM through integrins, p21cip1 will not be down-
regulated and therefore progression though the cell cycle will halt. This block in the 
cell cycle is one of the cells’ in-built tumour protective mechanisms.   
The majority of the studies investigating the mechanisms by which integrins control 
the cell cycle have been carried out using cells in suspension as the integrin inactive 
condition (Aplin and Juliano, 1999; Aplin et al., 2001).  This does not truly represent 
the direct influence of integrins as many other changes occur in cells in suspension, 
such as cell shape, the cytoskeleton and cell-cell adhesions.  It is only by deleting 
integrins directly in situ, without changing any of these additional effects, can the 
true effect of integrin control be studied.  In addition, fibroblasts are often the cell 
type used, so how integrins regulate proliferation at the early stages of the cell cycle 
in epithelial cells is not as well understood (Walker and Assoian, 2005).  
3.3.3 Control at G2/M 
Recent reports have also provided evidence for the role of integrins in later stages of 
the cell cycle including M phase and cytokinesis (Reverte et al., 2006; Streuli, 2009; 
Taddei et al., 2008; Toyoshima and Nishida, 2007).  The formation of the normal bi-
polar spindle and normal cytokinesis was disrupted in cells that had a mutation in the 
β1 integrin subunit cytoplasmic domain which prevented it becoming fully functional.  
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The mutant cells could enter into mitosis, but the correct assembly of microtubules 
from the centromere was inhibited, therefore showing that full integrin function is 
required for execution of cytokinesis (Reverte et al., 2006). 
This result was further supported by reports showing that integrin adhesion controls 
the mitotic spindle axis, with myosin X and microtubule proteins such as EB1 
involved with linking integrins to the spindle pole (Toyoshima and Nishida, 2007). In 
addition, phosphatidylinositol-3,4,5-triphosphate (PtdIns(3,4,5)P3) in the plasma 
membrane, the dynein/dynactin motor protein complex along with integrin adhesion 
have been shown to be essential for the correct spindle orientation and mitosis 
(Toyoshima et al., 2007). The role of integrins in cytokinesis has also been shown in 
the mammary gland where β1 integrin was deleted from the basal cells. The loss of 
β1 integrin altered the axis of basal cell division which was crucial in the maintenance 
of the stem cells niche in the mammary gland (Taddei et al., 2008). 
In summary, integrins are critical regulators of cell proliferation and impart their 
influence at many different points of the cell cycle.   Progression through the cell 
cycle requires both stimulation from GFs and control by integrins and both receptors 
cooperate together to ensure that proliferation is correctly regulated. The precise 
mechanism by which specific integrin subunits control proliferation is unknown in 
epithelial cells, as many mechanistic studies have been carried out in fibroblasts or 
using cell in suspension. Do different integrin subunits regulate proliferation 
differently? Is the control through the ERK/MAPK pathway or other signalling 
pathway.  It is these questions which I am going to address in this project.  
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4. Integrins in the Mammary Gland 
In this project, the mammary gland and mammary epithelial cells are used to further 
investigate the mechanism of integrins in proliferation regulation in epithelial cells.  
To understand the role that integrins have in this system, it is important to briefly 
discuss the structure of the tissue, particularly the mouse mammary gland and the 
known role that integrins have for the function and development of the mammary 
gland. 
4.1 Mammary Gland Development and Proliferation 
The mammary gland comprises of two compartments, the epithelium and the stroma.  
The epithelia consist of two layers, a luminal layer of specialised secretory cells and a 
basal layer of contractile myoepithelial cells. Both are surrounded by a basement 
membrane that separates them from the stroma (Figure 8).  The basement 
membrane is a flexible sheet of specialised ECM that provides a scaffold to which the 
cells can adhere.  It is composed of large networks of laminin and collagen IV that 
are bridged by nidogen proteins and the large heparin sulphate protein perlecan.  The 
stroma contains fibronectin, fibrillar collagen, tenascin and other protein components. 
It contains stromal cells, such as fibroblasts, myofibroblasts and adipocytes, and 
provides support for the epithelia (Richert et al., 2000).  
Development of the mammary gland is primarily postnatal.  Before the onset of 
puberty, only very basic ductal quiescent structures are present in the mammary 
gland.  During puberty, stimulated by estrogen and EGF, extensive ductal growth 
occurs and there is elongation and branching at the terminal end buds leading to the 
epithelium being organised into a branching network of ducts ending in terminal duct 
lobular units (TDLU) (Hennighausen and Robinson, 2001). During pregnancy in the 
mouse mammary gland, there is a massive burst of proliferation leading to the 
formation of alveolar and lobular structures which become denser and spread 
throughout the whole fat pad as pregnancy progresses.  The proliferation burst is 
stimulated by both steroid hormones, such as progesterone , peptide hormones such 
as prolactin, and extracellular factors such as Receptor activated by NF-κB Ligand 
(RANKL) and Wnt (Hennighausen and Robinson, 2005).  In the alveoli, the luminal 
and myoepithelial cells are arranged around a central lumen into which milk is 
secreted during lactation (Figure 8).  Along the ducts, the myoepithelial cells form a 
continuous layer along the basement membrane; therefore, the luminal cells have 
very little direct contact with the ECM.  However, in the alveoli during pregnancy, the 
arrangement of myoepithelial cells is stretched into a basket weave arrangement and 
the luminal cells can therefore contact the basement membrane directly (Streuli, 
2003). 
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Figure 8: Schematic illustration of the normal human breast. 
The functional units of the mammary gland are the ducts and terminal ductal 
lobular units (TDLUs). The ducts connect the TDLU’s to the nipple where the 
milk is released on pregnancy.  The TDLU and ducts are protected by a layer 
of adipose tissue.  Cross sections of the duct, alveoli and TDLU show the two 
major cell types that are lining the ducts and lobules; the luminal epithelial 
cells and the myoepithelial cells.  The luminal cells form hollow acini in the 
ducts and are attached to the myoepithelial cells and the laminin rich 
basement membrane.  The basement membrane separates the cells from the 
stroma and maintains the correct cellular architecture.  The stroma contains a 
variety of ECM proteins such as fibronectin and collagen as well as cells such 
as fibroblasts.  The basal, lateral and apical cell surfaces are indicated in an 
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Once lactation has finished and the secretary epithelial cells undergo apoptosis, the 
alveolar structures collapse and the gland remodels itself into the pre-pregnancy 
state.  
The initial wave of epithelial cell proliferation occurs during the first six days of 
pregnancy with 25-30% of cells labelled with tritiated thymidine (Traurig, 1967).  
Approximately 10% of the cells undergo S-phase throughout the rest of the 
pregnancy, which rises to 20% during early lactation.  This initial burst is stimulated 
by synergy between progesterone (Pg) and prolactin.  However not all epithelial cells 
respond to Pg directly and undergo proliferation in a Pg dependent manner.  Pg 
functions in a paracrine mechanism, whereas it is secreted by a population of 
epithelial cells and acts on neighbouring Pg receptor containing cells, creating a 
population of dividing and non-dividing cells (Oakes et al., 2006).  A similar paracrine 
mechanism is true for both estrogen and prolactin (Naylor et al., 2003).  Wnt4 and 
RANKL are both targets for Pg signalling and may be the factors directly responsible 
for induction of cell cycle as the RANKL target, NFκB, is required for cyclin D1 
activation.  Both Wnt4-/-, RANKL-/- and RANK-/- transgenic mice all had failed 
alveolar development during pregnancy due to a decrease in proliferation (Brisken et 
al., 2000; Fata et al., 2000).  Therefore proliferation is the mammary gland is 
regulated by a variety of factors from steroid and peptide hormones as well as 
growth factors, but signals are required from the epithelial microenvironment through 
integrins for the cells to undergo proliferation during pregnancy(Li et al., 2005). 
4.2 Integrin Expression in the Mammary Gland 
Integrins have key roles in mammary gland biology.  They regulate morphogenesis 
and development of the tissue and are essential for epithelial survival and alveolar 
proliferation and differentiation (Naylor et al., 2005; Taddei et al., 2003).  The 
difference between the luminal and myoepithelial cells contact with the ECM and their 
unique functions is reflected in their integrin expression.  Using immuno-
histochemical analysis, it was revealed that luminal epithelial cells express the 
integrin subunits α2, α3, α6, β1 and β4.  Myoepithelial cells express the same 
integrin subunits as the luminal cells, as well as subunits α1, α5, αv, β3 and β5 
(Taddei et al., 2003).    The integrin heterodimers are primarily localised to the basal 
surfaces of the cells where they can contact the ECM, but α2, α3, α6 and β1 subunits 
are also present on the lateral surfaces of luminal cells (Prince et al., 2002; Shaw, 
1999) (Table 1). 
Integrin mediated adhesion to the ECM has been shown to play an important part in 
regulating stem cell function and maintenance (Ellis and Tanentzapf, 2010).  In the 
mammary gland, integrins have been used as a marker to purify mammary stem 
cells (Visvader, 2009).  Cells expressing high levels of both β1 and α6 integrins (also  
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Integrin Ligands 
Localisation in 
Mammary Epithelial 
Cells 
Implications in 
Breast carcinoma 
α1β1 Collagen, Laminin Myoepithelial cells 
– basal surface 
 
Tumour cell 
invasive potential 
 
α2β1 Collagen, Laminin 
Luminal and 
myoepithelial cells 
– basal and lateral 
surfaces 
Tumour cell 
invasive potential 
α3β1 Laminin 5 (α3Aβ3γ2) 
Luminal and 
myoepithelial cells 
– basal and lateral 
surfaces 
Invasive potential, 
migration, 
activation on 
MMPs, EMT 
induction via uPAR 
α5β1 Fibronectin Myoepithelial cells 
– basal surface 
EMT induction 
α6β1 Laminin 
Luminal and 
myoepithelial cells 
– basal and lateral 
surfaces 
Tumour cell 
survival and 
growth 
α6β4 Laminin 
Luminal and 
myoepithelial cells 
– basal surface 
Tumour cell 
survival, migration 
and invasive 
potential 
αvβ3, αvβ5 Vitronectin, Fibronectin Myoepithelial cells 
– basal surface 
Migration, MMP2/9 
activation, 
metastasis 
 
Table 1: Integrins in the Mammary Gland, their Ligands, Localisation and 
Implications in Tumourigenesis and Breast Carcinoma.   
Adapted from information in (Taddei et al., 2003). 
39 
 
known as CD29 and CD49f respectively) as well as low levels of the epithelial marker 
CD24, were able to regenerate an entire mammary gland and therefore have been 
characterised as mammary stem cells (Shackleton et al., 2006; Stingl et al., 2006). 
In addition, progenitor cells (or luminal committed stem cell progeny) have also been 
shown to express high levels of β3 integrin (CD61) (Pontier and Muller, 2009).  
Mammary stem cells are found rested on the basement membrane in the basal layer 
of the mammary gland epithelium, which is known as the stem cell niche.  Integrins 
have been shown to be crucial in the maintenance of stem cell niche, as deletion of 
β1 integrin in the mammary basal cells depletes the mammary stem cell population 
and the regenerative potential of the mammary gland is destroyed (Taddei et al., 
2008).   
4.3 Integrins in Mammary Gland Proliferation  
The function of β1 integrin has been studied in the context of normal mammary 
epithelium proliferation, which occurs during pregnancy.  β1 integrin was first shown 
to be involved in the control of proliferation during normal mammary gland 
development when it was disrupted in the mouse mammary gland by the expression 
of a chimeric β1/CD4 construct under the control of the mammary gland specific 
MMTV promoter (Faraldo et al., 1998).  This construct does not bind extracellular 
ligands, and therefore acts as a dominant negative mutant of β1 integrin.  Epithelial 
cell proliferation rates were decreased at mid-pregnancy resulting in underdeveloped 
glands and there was a lack of activation of both ERK and JNK MAPKs (Faraldo et al., 
2001). However, interpretation of this data is complicated as the transgene may act 
as an antagonist or an agonist depending on its expression level. Therefore the link 
between β1 integrin and proliferation was verified using a genetic approach where β1 
integrin was knocked out in the luminal mammary epithelial cells using a CreLoxP 
system.  The knockout of β1 integrin induced a disorganised  alveolar morphology 
and proliferation was strongly inhibited, corresponding with an increase in expression 
of the cell cycle inhibitor p21(cip1) (Li et al., 2005). Control of mitotic spindle 
orientation by β1 integrin during M-phase of cell cycle is also essential for the 
regenerative potential of the mammary gland through stem cells.  Deletion of β1 
integrin in basal cells leads to cells dividing in the incorrect orientation and are 
unable to give rise to the correct progeny (Taddei et al., 2008).  These studies 
suggest an important role for β1 integrin in regulating mammary epithelial cell 
proliferation during normal development and in maintaining the stem cell niche, 
however the exact mechanisms by which β1 integrin imparts its control on the cell 
cycle in mammary epithelial cells is still largely unclear.  This is the major question 
which I address in this thesis (Chapter 3).  
The answer to the question is an important one.  Proliferation, adhesion and tissue 
morphology are all key characteristics that are all aberrantly altered in breast cancer, 
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therefore understanding the basic mechanistic controls that integrins exert on 
proliferation, could lead to new avenues in the treatment of breast cancer.  
5. Breast Cancer 
Breast cancer is the most common cancer in the UK, with almost 45,700 women 
being diagnosed in 2008 and each year in the UK around 12,000 women and around 
70 men die from breast cancer (UK, 2010).  Mammary glands are subjected to 
constant and varying extracellular controls, by for example steroid hormones and 
growth factors which influence its development and function.  Deregulation of these 
complex processes by disruption of the signalling pathways through mutations may 
explain the prevalence of breast cancer. 
The most commonly mutated or incorrectly regulated proteins in breast cancer are 
the growth factor receptors, ErbB2 and  Epidermal Growth Factor Receptor (EGFR), 
the growth factor signalling proteins; k-Ras and c-Src, and cell cycle regulators cyclin 
D1, p53 and RB (Toms, 2004).  However it is now becoming clear that functional 
aberrations also occur in adhesion signalling proteins such as FAK, p130Cas and the 
GEF β-pix (Cabodi et al., 2006; Lark et al., 2005). 
5.1 Breast Cancer Progression 
Cancer development and progression occurs by the accumulation of selective genetic 
events over time resulting in increased malignancy.  Many factors contribute to this 
progression and in breast cancer it is manifested through sequential stages of defined 
pathological and clinical features (Figure 9).  Most breast cancers arise from luminal 
cells within ducts or lobules, and the cells may or may not contain an inherited 
mutation such as BRCA, but they can become atypically hyper-proliferative when 
they acquire additional genetic changes. These genetic changes can cause over-
stimulation of the cell cycle, suppression of apoptosis or cellular immortalisation. The 
cells also lose their positional control within ducts which is in contrast with 
proliferation during pregnancy where the epithelial cells always remain in the correct 
location (Russo and Russo, 2004). The hyperplasia can progress to an epithelial neo-
plastic hyperplasia in situ by further mutations in growth factor receptors and steroid 
hormones receptors leads to lesions known as Ductal Carcinoma In Situ (DCIS) or 
Lobular Carcinoma In Situ (LCIS).  The cells within DCIS or LCIS are still separated 
from the stroma by the layer of myoepithelial cells and the basement membrane 
(Figure 8). This stage is considered a precursor stage to invasive cancer. 
Progression to invasive breast cancer (IBC) occurs when the malignant cells acquire 
further genetic changes and are able to migrate through the basement membrane 
and into the surrounding stroma (Figure 9).  The myoepithelial cells are outnumbered 
by the expanding cancer cell population and eventually disappear  
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The four main stages of breast cancer progression are normal ductal tissue, 
atypical hyperplasia, carcinoma in situ and invasive carcinoma.  The normal 
mammary gland is composed of hollow alveolar structures (indicated).  Abnormal 
uncontrolled proliferation of a normal cell leads to atypical hyperplasia and 
subsequently ductal carcinoma in situ (DCIS). DCIS displays a phenotype where 
the abnormal cells begin to fill the luminal space and therefore display a 
disorganised morphology.  During invasive carcinoma, the basement membrane 
breaks down and the malignant cells migrate into the stroma and the hollow 
luminal structures are no longer visible.  Rounds of clonal expansion are indicated 
and putative cancer stem cells (CSC) are also defined. 
Figure 9: Breast Cancer Progression 
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(Barsky and Karlin, 2006).  The basement membrane breaks down becoming 
discontinuous and disrupted in the tumour (Hu et al., 2008).  The importance of the 
microenvironment in cancer progression is becoming more apparent as changes 
directly impact on the malignancy of the cancer cells (Joyce and Pollard, 2009).  A 
primary malignant cancer can metastasize to distant locations, for example, bone, 
liver and brain are most comment in breast cancer.  
There is also evidence that breast cancer is derived from multi-potent stem cells, as 
a subset of tumour cells have been isolated and are able to initiate new tumour 
formation.  They have therefore been designated putative cancer stem cells (Al-Hajj 
et al., 2003).  Using a variety of surface markers including low of the epithelial 
marker CD24 and high levels hyaluronic–acid receptor CD44, the cells identified 
exhibited cancer stem cell behaviour (Shipitsin et al., 2007). 
These cells exhibited highly invasive and metastatic properties as well as increased 
MMP2 and MMP-9 activity and CD44 has been implicated in epithelial to mesenchymal 
transition (EMT) (Pontier and Muller, 2009). Tumours that are enriched in these 
undifferentiated cancer stem cells are resistant to therapy, more aggressive and 
prone to metastasis and are more likely to relapse, therefore therapeutic targeting of 
these cells promises to be a fruitful avenue to pursue. 
5.2 Breast Cancer Markers and Classification 
Breast cancer is a very heterogeneous disease and therefore it is classified into many 
subtypes using many molecular predictive and prognostic markers. The subtype of 
breast cancer determines decisions about a patient’s treatment and predicting the 
response to a particular therapy. They include the status of the steroid hormone 
estrogen (ER) and progesterone receptors (PR), EGF receptor ErbB2 (Her2) status.  
Breast cancers are primarily classified into two subtypes on diagnosis depending on 
the presence of ERα in their nuclei (ER positive or negative).  Whether the tumour is 
hormone-dependent or –independent determines if endocrine treatments, such as 
the ER antagonist, tamoxifen, should be administered (Sommer and Fuqua, 2001).  
ER-positive tumours often respond favourably to therapy and therefore have a 
significantly better outcome.  Further classification using mRNA gene expression 
profiles can separate breast cancers into 5 classes; Luminal A and B (ER positive), 
Her2+ (mainly ER negative), basal-like (mainly ER-, PR- and Her2-) and normal 
breast like (Sorlie et al., 2001).   
Breast cancers expressing higher levels of growth factors such as EGFR and ErbB2 
are often ER negative indicating a subset of tumours select alternate mechanisms to 
bypass the alternate normal estrogen induced mitogenic pathway (Cui et al., 2005). 
The ErbB2 gene is amplified in 10-30% of breast cancers and is associated with a 
high proliferative index that often has a poorer outcome.  With the development of 
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novel anticancer drugs that target this receptor such as the monoclonal antibody 
trastuzumab (herceptin), the prognosis of these patients has improved (Mori et al., 
2002).   
5.3 Focal Adhesion Proteins and Breast Cancer 
Changes in focal adhesion proteins are now becoming more associated with breast 
cancer as influence of the microenvironment in breast cancer initiation and 
progression has become more apparent.  FAK is one such protein which has been 
associated with poor outcome and an aggressive phenotype of IBC (Lark et al., 2005) 
and increased levels of FAK are observed at early stages of breast cancer, such as 
DCIS  suggesting that it is an early event in breast tumourigenesis (Lightfoot et al., 
2004).  In a knock out model, FAK has been suggested to modulate the transcription 
of genes involved in cancer progression and metastasis such as Src, Erb and p130Cas 
through a common set of transcription factors such as p53 (Provenzano et al., 2008).  
The established role of FAK as a primary signalling node for many pathways such as 
survival, proliferation, migration, invasion, angiogenesis in endothelial cells and the 
regulation of cancer stem cells makes it a potential target for treatment.  Many small 
molecule inhibitors  (PF-573,228; PF-562,271 and NVP-226) that  inhibit FAK kinase 
activity or autophosphorylation are currently being developed by different 
pharmaceutical companies and some have moved in to phase I clinical trials, but it 
remains to be seen if these compounds can prove effective in patients (Hao et al., 
2009) (Luo and Guan, 2010). 
As FAK is activated following integrin-ECM engagement in normal cells, the aberrant 
FAK activity in breast cancer, implicates that integrins may also have an important 
role in breast cancer development.  In the next section, I am going to focus on the 
evidence for the involvement of some integrin subunits (α6β4, β1 heterodimers and 
αv heterodimers) in breast cancer tumourigenesis. 
 
6. Integrins in Breast Cancer 
The idea that integrins are involved in tumourigenesis is not a new one.  Their ability 
to promote cell proliferation, survival, migration and cell anchorage, all processes 
that are disrupted in cancer, suggests the role of integrins in tumour formation and 
progression (Guo and Giancotti, 2004; Jin and Varner, 2004).  It is because of these 
roles they are an attractive target for cancer therapy and integrin antagonists such 
as cilengitide are currently in clinical trials (Desgrosellier and Cheresh, 2010). 
Integrin expression is generally retained in tumour cells, especially by epithelia where 
integrin heterodimers such as α6β4, α6β1, α2β1 and α3β1 are generally present, 
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though their expression levels may be altered (Eble and Haier, 2006).  However, 
some integrin heterodimers (αvβ3, αvβ6 and α5β1) are expressed at very low levels 
in normal tissues can be highly up-regulated in tumours (Rathinam and Alahari, 
2010).  These heterodimers are often associated with survival, migration and 
proliferation, and correlate with disease progression and poor patient outcome.  
Some integrin heterodimers (α2β1) however have been demonstrated to inhibit 
tumourigenesis, reduce dissemination and could function as a tumour suppressor 
(Kren et al., 2007; Zutter et al., 1995), but other studies show that α2 subunit 
promotes breast cancer tumourigenesis (Lochter et al., 1999).  As the expression of 
integrin subunits are cell type specific, it will therefore be discussed in the context of 
breast cancer. 
6.1 α6β4 Integrin Heterodimers 
The integrin dimer α6β4 has been suggested to be involved in breast cancer 
progression by enhancing carcinoma survival and invasion through the PI3K/Akt 
signalling pathway (Bon et al., 2007; Mercurio et al., 2001; Shaw et al., 1997).  In 
carcinoma cells, α6β4 localises to the leading edge of migrating cells and associates 
with F-actin (Rabinovitz and Mercurio, 1997), therefore suggesting α6β4 performs an 
alternative role in cancer compared to normal cells where it forms hemidesmosome 
adhesions with intermediate filaments.   The exact stimuli and mechanism that 
causes this change in behaviour is unknown.  It has been suggested to be involved 
with the EGF receptors and in particular ErbB2 as α6β4 heterodimers were shown to 
be associated with ErbB2 in a number of breast cancer cell lines (Falcioni et al., 
1997).  
The cooperation in signalling between β4 integrin and ErbB2 was demonstrated to 
promote tumourigenesis in the mammary gland.  When β4 signalling was attenuated 
in an in vivo mouse model of ErbB2-induced carcinoma, reduced mammary tumour 
onset time and invasion into the stroma was observed (Guo et al., 2006).  In vitro, it 
was demonstrated that ErbB2 forms a complex with β4 integrin and promotes 
activation of the transcription factors STAT3 and c-jun.  STAT3 activation disrupted 
cell adhesion and polarity, whereas c-jun activation was required for 
hyperproliferation.  α6β4 integrin can also directly regulate the expression of ErbB3 
at the translational level resulting in the increased formation of the ErbB2/ErbB3 
heterodimer which amplifies PI3K/Akt signalling as part of a positive feedback 
mechanism (Folgiero et al., 2007).  By cross-linking α6β4 integrins, the interaction 
between α6β4 and EGF receptors was further illustrated, showing that the clustering 
of EGFR, promotes Rho activation and increases motility (Gilcrease et al., 2009).  In 
addition, α6β4 has been shown to directly regulate expression of genes such as 
metastatin that are associated with metastasis, cell motility and invasion (Chen et 
al., 2009). 
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In vivo, there is a slight trend in decreased survival in patients with high β4 integrin 
expressing tumours, but it was not statistically significant (Diaz et al., 2005). High α6 
integrin expression in breast carcinoma strongly correlates with low survival rates 
(Friedrichs et al., 1995) and metastasis (Mukhopadhyay et al., 1999) therefore 
supporting the in vitro data. 
6.2 β1 integrin Heterodimers 
β1 integrin heterodimers have been widely implicated in various stages of breast 
tumourigenesis over the years with data from both in vivo and in vitro studies 
showing the importance of this subunit in breast cancer progression  (Gui et al., 
1995; Mechtersheimer et al., 1993; Shaw, 1999; Wewer et al., 1997).   
In general, it appears that a loss in expression of β1 integrin heterodimers is 
associated with larger tumours (Jonjic et al., 1993) and increased invasiveness (Gui 
et al., 1995).  However, it is currently unclear whether this relates to patient survival 
as some studies have shown a decrease in β1 integrin expression having no 
correlation (Berry et al., 2004), a poorer (Gonzalez et al., 1999) or a better outcome 
(Yao et al., 2007).  
In vitro data on the role of β1 integrin in breast cancer is just as inconsistent.  
Function-blocking anti-β1 antibodies inhibited the formation of polarised acinar 
structures and increased apoptosis in normal cells cultured in 3D Matrigel culture 
indicating the requirement for β1 integrin in normal cell function.  However, when the 
tumour cell line T4-2, which over-expresses EGFR was similarly treated with β1-
integrin function-blocking antibody, the T4-2 colonies reverted to a ‘normal’ 
phenotype, stopped proliferating, formed polarised acini structures and levels of 
EGFR were reduced, thereby linking active β1 integrin with tumourigenesis (Weaver 
et al., 1997) (Wang et al., 2002).  A similar reversion phenotype was observed in a 
number of different breast cancer cell lines cultured in Matrigel and treated with a β1 
integrin inhibitory antibody indicating that it was not purely down to the cooperation 
between EGFR and β1 integrin (Park et al., 2006).  
There is also some evidence to indicate involvement of α5β1 integrin and its 
downstream signalling pathway thorough ILK, in the mechanism by which the growth 
factor angiopoietin-2 mediates an enhanced invasive phenotype and breast cancer 
metastasis (Imanishi et al., 2007).  Interactions between β1 integrin and the GTPase 
Rab25, that regulates membrane integrin recycling, suggest that this interaction 
could promote migration and tumour invasiveness, particularly through the 
association of Rab coupling protein (RCP) and EGFR (Caswell et al., 2008; Caswell et 
al., 2007). 
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The role of β1 integrin in mammary gland tumourigenesis in vivo was investigated 
genetically by disrupting β1 integrin in transgenic mice expressing the polyomavirus 
(PyV) middle T (MT) oncogene under the transcriptional control of the mammary 
mouse tumour virus (MMTV) promoter that functions as a model of human breast 
cancer. It was demonstrated that functionally active β1 integrin was required for 
tumour induction by the MMTV and ablation of β1 integrin results in a proliferation 
block with no observed increase in apoptosis (White et al., 2004).   The observed 
proliferation block is consistent with the studies carried out in Matrigel  and could be 
due to an increase in p21Cip1  as previously observed (Li et al., 2005). 
The exact role of β1 integrin in breast cancer tumourigenesis and progression 
remains unclear, however a number of targeted therapies against β1 integrin are 
currently being developed.  A humanised monoclonal antibody against α5β1, namely 
Volociximab has successful completed phase I clinical trials and its clinical efficacy is 
further being investigated (Ricart et al., 2008).    Further to this, ATN-161, a non-
RGD based integrin binding peptide has been shown to block breast cancer growth 
and metastasis in vivo and offers potential for treatment in the future (Khalili et al., 
2006). 
6.3 αv Integrin Heterodimers 
Integrins of the αv family, particularly αvβ3 and αvβ5, are proposed to have a role in 
tumour progression, specifically in invasion and metastasis in breast cancer (Guo and 
Giancotti, 2004; Hood and Cheresh, 2002).  αvβ3 can recruit and activate MMP-2 
therefore facilitating invasion (Brooks et al., 1996).  MMPs break down the 
surrounding ECM, enabling the cell to migrate through the ECM to surrounding 
tissues.  αvβ3 associates with the urokinase plasminogen activator (uPA) receptor 
(uPAR) through the kringle domain of uPAR (Tarui et al., 2006).  Pro-uPA binds to 
uPAR, activating it and it thereby converting plasminogen to plasmin, another matrix 
degrading protease that further degrades the ECM and also activates MMPs 
(Chapman and Wei, 2001).  In addition, the plasminogen activator inhibitor-1 (PAI-1) 
has been show to alter the activity of uPA and lead to sustained ERK signalling in 
breast cancer cells (MCF-7)(Webb et al., 2001).  The ligand, uPA, has also recently 
been demonstrated to be able to bind both uPAR and αvβ5 integrin simultaneously 
though a ‘connecting peptide’ and stimulate simultaneously intracellular signalling 
pathways and migration (Franco et al., 2006).  
In breast cancer, the function of αv integrins has been linked with the secreted 
glycoprotein osteopontin.  Osteopontin binds to αvβ1, αvβ3 and αvβ5 integrin 
heterodimers, is over-expressed in a high proportion of breast cancers and is 
associated with an aggressive phenotype and poor patient prognosis (Rudland et al., 
2002). It was shown that increased expression of αvβ3 integrin could sensitise 
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tumour cells to malignancy promoting molecules such as osteopontin, therefore 
increasing tumour aggressiveness by promoting bone metastasis (Furger et al., 
2003).   
αvβ3 activates downstream oncogenic signalling pathways, for example αvβ3 can 
activate c-Src through a functional interaction between the β3 cytoplasmic tail and 
the c-Src SH3 domain, resulting in enhanced phosphorylation of known c-Src 
substrates involved in proliferation, survival and tumour growth in breast cells 
(Huveneers et al., 2007).  β3 integrin has also been linked in vivo with the induction 
of EMT through the TGF- β pathway in mammary epithelial cells (Galliher and 
Schiemann, 2006).  This is suggested to occur through physical interaction of β3 with 
the TGF β Type II receptor leading to phosphorylation of the cytoplasmic tail of β3 by 
c-Src.  This appears to promote stimulation of p38 MAPK during proliferation and 
invasion (Galliher and Schiemann, 2007). β3 integrins have also been identified as a 
putative marker for cancer stem cells in three different mouse models of mammary 
tumourigenesis (Vaillant et al., 2008). 
Whilst αv heterodimers are an attractive target for potential breast cancer therapies, 
as they are up regulated in tumour cells and angiogenic endothelial cells, their 
efficacy in vivo has been much debated.  Both RGD peptides, like the αvβ3 and αvβ5 
inhibitor cilengitide, and humanised function blocking antibodies, such as 
etarcizumab and CNTO 95 that target αv integrin subunits, have entered phase II 
and III clinical trials for other cancers, like glioblastoma, however the effectiveness of 
these potential therapies has not been shown in breast cancer (Desgrosellier and 
Cheresh, 2010). 
7. Background and Aims of the Project 
There is an abundance of evidence that a variety of integrin heterodimers are 
involved in breast cancer tumourigenesis, progression and metastasis, but for them 
to be a realistic potential target for treatment, their precise role in the control of 
proliferation, survival and migration must be established in normal MECs.  Whilst it is 
known that β1 integrins are involved in proliferation control of MECs and other cell 
types through genetic studies in vivo, the exact mechanism of how β1 integrin 
regulate cell cycle is not entirely clear (Aszodi et al., 2003; Li et al., 2005; Raghavan 
et al., 2000).  Many mechanistic cell culture studies investigating integrin control of 
cell cycle and proliferation have been carried out in fibroblasts and compared 
attached cells with cells in suspension (Assoian and Schwartz, 2001)(Aplin et al., 
2001). Although these studies do reveal some basic mechanisms behind the 
cooperation between GF and integrins in proliferation regulation, they do not allow 
conclusions to be drawn about which discrete integrins are involved in cell cycle 
regulation.  Cells in suspension undergo many additional changes, as well as integrin 
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inactivation such as alterations in cell shape, cell-cell adhesion and cytoskeleton 
rearrangements, all of which could affect cell cycle progression (Huang et al., 1998; 
Ingber et al., 1995).  By genetically deleting integrins in MECs in situ, without the 
need for replating, conclusions can be drawn about integrin specific regulation of cell 
cycle.   
Commonly used cell lines often undergo changes to genomic structure and the 
normal cell cycle machinery is disrupted in order to escape senescence, therefore 
their uses are limited to study proliferation mechanisms (Romanov et al., 2001).  
Primary cells are the preferential system in which to study the cell cycle, but 
proliferation in culture is limited and this can restrict their uses.  Therefore, there is a 
requirement for primary cell culture models to be established in which proliferation in 
primary MECs can be studied over a longer period of time.  The establishment of a 
suitable cell culture system in which the window of proliferation of MECs is increased 
is crucial to be able investigate the mechanism by which integrins regulate cell cycle. 
New breast cancer progression models are constantly being generated and the 
MCF10a breast cancer progression cell line series is one such model.  Integrins are 
rarely studied when assessing these models for their effectiveness to model breast 
cancer and it is important to establish that integrin expression reflects the particular 
stages of breast cancer. 
The aims of my PhD project are therefore as follows: 
 Develop and characterise a primary MEC culture system whereby the β1 
integrin gene can be deleted in situ, without the need for replating.  This will 
allow the discrete role of β1 integrin to be studied in relation to cell function, 
specifically proliferation. 
 Establish a methodology to increase the proliferation window of primary MECs 
in conventional 2D culture in order to be able to study cell cycle over a longer 
period of time. 
 Using the newly established cell culture systems, determine the downstream 
signalling mechanisms by which β1 integrin regulates cell proliferation in 
MECs. 
 Investigate the role of β1 integrins and the morphology in 3D culture of the 
MCF10a breast cancer progression cell line series to determine whether it is a 
suitable model for breast cancer progression. 
The outcomes of these aims are presented in the manuscripts in the following three 
chapters. 
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Abstract 
The use of cell culture models is the principal and fundamental technology used in 
understanding how mammalian cells work.  However, cell cultures often have 
considerable problems; the cell lines that are selected for long term culture in 2D 
conditions usually have chromosomal abnormalities resulting in an indefinite lifespan 
while some primary cultures have such limited lifespan that their use is restricted and 
genetic manipulation can be problematic. The proliferation of primary mammary 
epithelial cells (MECs), a common model used in researching breast cancer, is limited 
to a few days which makes it very difficult to study them longer term.  Here we 
describe the establishment of a new culture system to allow the analysis of cultures 
of luminal primary MECs over many days. We also examine the detailed proliferative 
behaviour of primary MECs in 2D monolayer culture on collagen I and investigate 
ways it can be modified, using simple techniques.  
In 2D planer culture, primary MECs showed a burst of proliferation 48 hours post 
isolation, after which proliferation decreased. Addition of the growth factors, such as 
basic fibroblast growth factors, hepatocyte growth factor and Receptor Activator for 
Nuclear Factor κ B Ligand, other ECM proteins, or replating the cells to increase the 
mitogenic response did not maintain the proliferative potential of the MECs. However, 
culturing the cells in a 3D microenvironment directly following tissue extraction, 
isolating the 3D acini using PBS/EDTA and replating onto 2D surfaces to study 
proliferation, maintained the 3D in vivo proliferative potential of the cells.  
Manipulation of the cellular environment, using this novel method, can maintain the 
proliferative potential of primary MECs. This increase in the proliferation window will 
allow their use over a longer time period, hence enabling cell replication to be studied 
as an endpoint after gene transfer experiments in MECs. Our data reveals that the 
cellular environment has profound effects on the proliferative properties of the 
primary MECs. 
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Introduction 
Mechanisms of cell cycle regulation in metazoans have normally been studied in cell 
lines isolated from normal tissues or from cancer patients. Little is known about the 
control of proliferation in primary cell culture, prior to cellular crisis and cellular 
immortalization. Less is known about the mechanisms controlling normal epithelial 
cell cycle. We wish to define how the breast epithelial cell cycle is regulated, in order 
to understand the defects that occur during breast cancer progression.  
Historically, epithelial cells have been difficult to culture compared to other cell types. 
However, due to the progress in cell culture techniques over the past 20 years, 
epithelial cells are now routinely cultured and widely accepted as excellent models for 
many studies including cancer research (Debnath and Brugge, 2005). Mammary 
epithelial cells (MECs) are used to study epithelial cells in general, but also mammary 
specific functions such lactation and breast cancer. Primary MECs isolated directly 
from the mouse or human mammary gland are a preferred model compared to 
immortalised cell lines as they are more similar to cells in vivo (Aggeler et al., 1991; 
Smalley, 2010), without the numerous changes associated with immortalisation that 
can affect cell behaviour (Hopfer et al., 1996; Li et al., 2007). Studying end points 
such as differentiation and lactation in vitro, is now possible with the use of 3D 
culture techniques using reconstituted basement membrane (BM) such as 3D 
Matrigel and collagen gels and stimulation with hormones such as prolactin (Streuli et 
al., 1991). However, when proliferation over a longer period of time is required as an 
endpoint, it is often difficult to use primary cells.  
Normal primary MECs frequently have a very poor response to culture conditions, 
proliferating slowly, and undergoing apoptosis (Pullan et al., 1996) or becoming 
senescent (Ben-Porath and Weinberg, 2005). Occasionally cells can emerge from 
senescence through immortalisation, in which changes in genomic structure including 
telomere rescue, occur (Romanov et al., 2001).  However, immortalisation disrupts 
the normal cell cycle regulatory mechanisms, such as phosphorylation of Rb protein, 
limiting the appropriateness of immortalized lines for studying endpoints such as 
proliferation mechanisms. 
One strategy to understand proliferative mechanisms is to delete the genes or 
deplete expression of genes encoding cell cycle regulators.  While plasmid 
transfection is a standard strategy in established cell lines, primary cell cultures with 
limited lifespans require more sophisticated techniques.  The use of cre-mediated 
genes deletion of floxed-genes (Naylor et al., 2005) or shRNA expressing lentivirus 
are both alternative options for primary MECs.  However in some cases, the window 
of opportunity for doing this while maintaining proliferative potential is extremely 
limited as it can take at least 48 hours for the induced protein to be expressed or the 
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knock down target to be turned over, therefore the ability of the cells to proliferate at 
that time has significantly decreased. 
We have discovered that the optimal window for proliferation of primary luminal 
MECs is only approximately 3 days thus deleting a gene in time for its gene product 
to be turned over to functional analysis of cell cycle is unpractical. 
In this paper, we have explored growth factor (GF) and extracellular matrix (ECM) 
requirements for maximising the time frame of MEC proliferation in culture.  We find 
that manipulating the micro-environmental conditions for cells is able to extend the 
proliferation window sufficiently to analyse the consequences of deleting genes. 
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Materials and methods 
Primary mouse mammary epithelial cell culture  
MECs were isolated and cultured from pregnant ICR mice as described (Pullan et al., 
1996). All studies in this paper used primary MEC cultures. The cultures dishes were 
prepared as follows; Rat tail collagen I (isolated ourselves) was diluted in cold PBS to 
give a final concentration of 10 μg/ml and dishes were coated with 100 μl per cm2 
dish area, resulting in a coating density of 1 μg/ cm2. The extracellular matrix 
proteins laminin-1 (12 μg/ml), fibronectin (12 μg/ml) and vitronectin (3 μg/ml) were 
purchased from Sigma UK. The proteins were diluted to the specified concentrations 
in cold PBS. The ECM protein/PBS mixture was incubated overnight at 4oC or 1-
2 hours at 37oC. The dishes were washed three times with cold PBS. Engelbreth-
Holm-Swarm mouse sarcoma basement membrane matrix (3D Matrigel) was 
purchased from BD Biosciences. 3D Matrigel was defrosted on ice and spread over 
the culture plates using the end of a 1ml micropipette tip before incubating at 37oC 
for 30 mins to set. Both 2D ECM proteins and 3D Matrigel coated plates were 
conditioned with the serum/fetuin mix (see appendix methods), containing double 
the concentration of growth factors and antibiotics, for approximately 3-4 hours at 
37oC before plating the cells. 
Cells were cultured in complete growth media containing 5 μg/ml insulin, 1 μg/ml 
hydrocortisone (Sigma), 3 ng/ml epidermal growth factor (EGF),10% foetal calf 
serum (Biowest), 50 U/ml penicillin/streptomycin, 0.25 μg/ml fungizone and 50 
μg/ml gentamycin in Ham's F12 medium (Gibco). All cultures were maintained at 
37oC in a 5% CO2 atmosphere.  
2D and 3D EdU proliferation assay  
MECs were pulsed with 10 μM EdU(Click-iT™ EdU Alexa Fluor® 488 Imaging Kit 
# C10083 from Invitrogen), added to current media, for 8 hours to measure DNA 
synthesis and therefore the proliferation rate of primary MEC culture at different time 
points (Buck SB et al., 2008). The cells were fixed in 4% paraformaldehyde and 
visualisation of EdU labelled nuclei was carried out using EdU-Click reaction according 
to manufacturer’s instructions. EdU was detected by preparing fresh Click-iT™ buffer 
by mixing 1x Click-iT™ reaction buffer, CuSO4 , Alexa fluor-488 azide and 1x reaction 
and additive solution at the specified ratios. The cells were permeabilised using 0.5% 
Triton X100 and blocked 10% goat serum in PBS. The Click-iT™ reaction buffer was 
incubated for approximately 30 mins, protected from light. The cells were washed 
once using the wash solution provided and a normal immunoflourescence protocol 
was used to co-stain for other proteins (see below), protecting from light at all times. 
The labelled cells were mounted with ProLong® Gold anti-fade reagent (Invitrogen) 
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and visualised using a Zeiss Axioplan2 microscope equipped with a Hamamatsu 
ORCA-ER digital camera. Images were captured and processed using OpenLab 
software (Improvision UK). The cells were counted blind and the number of EdU 
labelled nuclei calculated as a percentage of the total DAPI stained nuclei. An average 
of 2000 cells was counted per experiment for a minimum of 3 independent 
experiments. 
Isolation of mammary gland acini from 3D Matrigel using PBS/EDTA 
MECs cultured on 3D Matrigel were incubated in sterile PBS/5 mM EDTA, scraped off 
the dish using a cell scraper or end of a 1ml micropipette, transferred to Falcon 
tubes, and incubated on ice for 5 mins with gentle shaking. This, together with wash 
from dishes, was transferred to a fresh Falcon tube and centrifuged (42 xg, 3 mins). 
Resulting acini were resuspended in fresh PBS/EDTA, incubated on ice for 5 mins, re-
centrifuged, washed in fresh media, and resuspended in the final volume of complete 
media and plated onto collagen I-coated substrata. Most acini adhered to the 
substrata within a few hours, and the cells migrated as sheets of cells onto the 
dishes. Cell migration was followed using an AS MDW live cell imaging system (Leica) 
over a 72 hour time period with x5 objective and images captured every 30 mins.  
Immunofluorescence staining in 2D and 3D 
Staining was as previously described using MECs fixed in 4% paraformaldehyde/PBS 
(10 mins, RT), and permeabilized in 0.2% Triton X100/PBS (5 mins, RT). The 
blocking reagent was 5% goat serum (Biosera). Primary antibodies that recognise 
cytokeratin 5 (AF138) (Covance), and alpha-tubulin (T-9026) (Sigma), and 
secondary anti-rabbit Alexa 594 and anti-mouse Alexa 488 antibodies (Invitrogen) 
were used. Nuclei were stained with Hoechst 33342 (1:10000 in PBS) for 2-3 mins. 
The coverslips were mounted onto twin frosted glass slides using ProLong® Gold 
antifade reagent (Invitrogen). The cells were visualised using a Zeiss Axioplan2 
microscope equipped with a Hamamatsu ORCA-ER digital camera and images were 
captured and processed using OpenLab software (Improvision UK).  
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Results 
Proliferation profile of primary mouse mammary epithelial cells in 
conventional 2D culture 
We aim to understand mechanisms of cell cycle regulation in luminal alveolar 
epithelial cells of normal, non-immortalised breast epithelium. Initially, we examined 
the proliferation kinetics of MECs isolated from mouse mammary gland towards the 
end of pregnancy (P16-P18) and cultured on collagen I-coated dishes (Fig. 1a). 
Approximately 40% of the cells were cycling 2 days following isolation, but the 
proliferation rate fell to less than 10% for the remaining time of analysis. Both 
luminal and myoepithelial cells are isolated during the preparation of MECs, and the 
proportion of myoepithelial cells is generally no more than 5-7%. The majority of EdU 
stained proliferating cells did not co-stain with the marker for myoepithelial cells, 
keratin 5, thus the proliferating cells are the luminal cell population (Fig.1aii).  
Similar proliferation characteristics were also seen in MECs isolated at different 
stages of pregnancy and development (Fig. 1b). MECs isolated at mid-pregnancy 
(P12-14), showed similar proliferation characteristics to those from P16-18, but the 
rate was initially less and extended a little longer (cf black and grey bars). MECs 
isolated from virgin mammary glands showed maximal proliferation at day 3 of 
culture, thereafter decreasing and remaining low after 5 days of culture (light grey 
bars). 
Thus although there are slight initial differences, MECs proliferate rapidly only for the 
first 48-72 h of culture, after which proliferation falls to <10% for as long as the cells 
survive in standard planar culture. We previously showed that after 4 d in culture, 
luminal MECs undergo substantial apoptosis (Pullan et al., 1996). These proliferation 
kinetics are different to cell lines or early passage cultures, in which mechanisms of 
cell cycle are usually studied. 
Growth factors or different ECM proteins cannot extend or enhance the 
proliferation window of primary MECs in 2D culture 
In order to examine how cell cycle is regulated in non-immortalised MECs using 
molecular genetic approaches, we aimed to find ways of extending this brief window 
of proliferation, because proteins frequently require several days to be turned over 
following their genetic ablation or knockdown.  
A key determinant of cell cycle in breast epithelia is growth factors. The previous 
experiments included EGF, insulin and hydrocortisone in the culture media, indicating 
that these factors are not able to maintain proliferation; moreover, adding fresh 
medium did not reactivate cell cycle. In the mammary gland in vivo, the growth 
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factors that stimulate proliferation during puberty and pregnancy are IGFs (whose 
action is mimicked by high levels of insulin in our cultures), Amphiregulin (whose 
effects are mediated by EGF in culture), Fibroblast Growth Factor-2 (basic FGF) 
(Ehmann et al., 2003), Receptor Activator for Nuclear Factor κ B Ligand (RANKL) 
(Gonzalez-Suarez et al., 2007; Kim et al., 2006) and Wnt3a (Olson and Papkoff, 
1994). To determine if these factors promote proliferation, MECs were cultured using 
amounts of bFGF, RANKL, or Wnt3a.  The concentrations were determined by 
performing a dose response experiments (See Appendix) or identifying 
concentrations in the literature that are known to have a physiological effect 
(Fig. 2a)(Aldridge et al., 2005; Kim et al., 2007). None of the growth factors showed 
any effect on the rate of proliferation compared to control cells. 
The cellular microenvironment is critical in regulating cell cycle  (Lee and Juliano, 
2004; Streuli, 2009), and ECM proteins can alter the proliferative response of luminal 
MECs (Woodward et al., 2000). MECs were cultured on different extracellular matrix 
(ECM) proteins and proliferation was assessed 4 d after plating cells on collagen I, 
laminin I, vitronectin, fibronectin or directly on the plastic of the culture dish 
(Fig. 2b). The proliferation of control cells on collagen I was approximately 8% (i.e. 
as in Fig. 1a and Fig. 2ai), but less than 5% on the other substrata. 
Thus, the proliferation potential of MECs cannot be extended or enhanced by 
manipulating the culture medium by addition of growth factors, or by altering the 2D 
ECM protein substratum.  
Replating does not restore the proliferation potential of primary MECs in 2D 
culture 
Contact inhibition and spatial restriction are negative regulators of epithelial cell 
proliferation. During cell-cell contact, the ligation of E-cadherin up-regulates the cell 
cycle inhibitor p27, blocking proliferation (St Croix et al., 1998). Since MECs on 
collagen I were nearly confluent at day 4 when the proliferation levels were very low 
(Fig. 1a) we reasoned that releasing contact inhibition by replating the cells might 
reactivate cell cycle. MECs were replated either at their proliferation peak, i.e. ~45% 
at 2-days after isolation, or once proliferation had decreased, i.e. <10%, after 4 days 
(Fig. 3a). Proliferation was analysed each day for 4 days following replating, but at 
no point did more than 5% of cells have EdU-labelled nuclei. 
Replating onto different ECM also did not promote proliferation; in fact collagen I 
showed the highest rate (Fig. 3b). The addition of a variety of growth factors such as 
HGF (Sunil et al., 2002) (not shown), bFGF, RANKL, or Wnt3a to complete media 
either alone or in combination, to replated cells also failed to promote proliferation 
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(Fig. 3c). MECs harvested from different pregnancy time points also failed to 
proliferate following replating (Fig. 3d). 
Thus, monolayer cultured MECs do not cease proliferating because they become 
confluent, but rather they enter an apparently irreversible quiescence. This 
quiescence cannot be rescued by trypsinising and replating the cells (as in cell lines) 
and appears to be irreversible under 2D growth conditions. Moreover, under these 
conditions, the cells do not undergo senescence, as judged by β-gal staining (data 
not shown). 
A novel method to prolong the proliferation window of primary MECs 
The culture of cells in 3D ECMs such as a Matrigel has been used extensively to study 
cell behaviour because it provides an environment more similar to that found in vivo 
than planar dishes (Debnath and Brugge, 2005; Stoker et al., 1990; Weigelt and 
Bissell, 2008). Consequently, we explored whether 3D culture might provide an 
opportunity to maintain or extend the proliferation window of primary cultures. MECs 
form spherical acini when cultured in 3D Matrigel (Fig. 4a). The proliferation rate of 
primary cells in these 3D structures over the course of 7 days had a similar profile to 
that cultured in 2D, with an initial burst of proliferation at day 2, which steadily 
decreased (Fig. 4b).  
The culture of primary MECs in 3D Matrigel mimics some of the conditions the cells 
are exposed to in vivo, with the presence of basement membrane proteins and a 3D 
structure. We hypothesised that, despite this loss in proliferation whilst culturing in 
3D, the intrinsic potential to undergo cell cycle may not be lost in those conditions. 
We therefore tested whether the proliferation potential of the cells could be 
maintained in 3D culture over a period of several days, such that when replated onto 
2D ECM, they efficiently enter cell cycle again.  To do this we tested whether i) 
plating the primary MECs directly on 3D Matrigel followed by ii) culturing the cells for 
several days in 3D, iii) isolating the acini from the 3D Matrigel, and iv) replating them 
onto 2D collagen, would reproduce the initial burst of proliferation many days after 
their initial isolation (Fig. 4c).  
Mammary acini were isolated from the 3D Matrigel in sterile PBS containing 5 mM 
EDTA, which retained the acinar structure of the MECs but removed the Matrigel 
(Fig. 4c). Isolated acini were transferred to pre-coated collagen I culture dishes onto 
which they settled. The cells migrated out of the 3D structure, proliferated and 
formed a monolayer on the 2D collagen (Fig. 4d, e).  
Other cell lines that form distinct structures when cultured in 3D Matrigel can also be 
isolated using EDTA /PBS. The mammary cell line, MCF10a, form spherical acini when 
cultured in 3D Matrigel (Debnath et al., 2003) . The MCF10a acini were isolated using 
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EDTA and analysed over 7 days using phase microscopy. The overall stricture of the 
acini spreading out onto the 2D surface was also revealed by staining for tubulin and 
analysed using confocal microscopy (Supp. Fig. 1). 
When MECs were plated as 3D acini for 2-days and then replated into 2D culture, 
proliferation peaked 2 days later, similar to primary MECs (Fig. 4fi).  Interestingly, 
these cells maintained a high level of proliferation (i.e. more than 20%) for a longer 
time period than cells plated onto a 2D substratum directly after tissue isolation 
(compared Fig. 4fi with Fig 1a). The duration of 3D culture before isolation did not 
affect this pattern of proliferation (Fig. 4fii, iii). Even after culture in 3D for 7-days 
when proliferation is reduced to 2%, the cells showed a dramatic cell cycle burst 
when replated into 2D cultures.  
Together, the data show that the process of removal of MECs from their in vivo 
environment and placing them in 2D culture disables their ability to proliferate over 
an extended period of time. By mimicking in vivo conditions using 3D Matrigel, we 
were able to maintain the proliferative potential of the MECs for at least 7 days, so 
that after replating into 2D culture, a high proportion of cells were able to enter cell 
cycle again. This provides an operational advantage for genetic manipulation of 
primary MECs because it permits sufficient time for gene deletion (using a cre-
mediated approach) or mRNA depletion with shRNA. 
3D culture maintains, but does not reset the ability for MECs to proliferate  
Cells in 2D culture lost the ability to proliferate after 3-4 days and replating the cells 
in 2D could not restore this. In contrast, cells in 3D culture retained the ability to 
proliferate when they were replated in 2D. We therefore determined whether 
culturing in 3D Matrigel could reset the ability of MECs to proliferate at the levels 
seen immediately after isolating cells from tissue, or whether it purely maintained the 
proliferation potential of the cells at the point that they were put into 3D Matrigel. 
Primary MECs were cultured for a varying amount of time in 2D on collagen the 
replated on 3D Matrigel. After 48 h, the MECs were isolated from 3D Matrigel using 
PBS/EDTA and replated back onto 2D collagen for a further 4-days. The proliferation 
was analysed by EdU over the course of the experiment (Fig. 5).  
When the cells were put into 3D Matrigel at the peak of their proliferation in 2D (i.e. 
day 2), and then recultured in 2D, the cells were able to attain a proliferation rate of 
13%. This was maintained for 2-days and declined thereafter (Fig. 5a). In contrast, 
when the cells had lost their ability to proliferate in culture in 2D for 3- or 5-days 
were plated on 3D Matrigel for 2 days and then replated back onto 2D collagen, the 
proliferation level was much lower with less than 10% of the cells being EdU positive 
(Fig. 5b and c). 
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These results show that 3D Matrigel acts to maintain the cells’ in vivo proliferation 
potential at the point they were put into 3D Matrigel.  It does not reset the cells 
proliferative potential to the point the cells they were isolated from the mammary 
gland. 
Discussion 
Limitations in primary MEC proliferation 
In this study, we have discovered that manipulating ECM dimensionality can 
profoundly affect the proliferative potential of primary MECs.  These cells lose their 
ability to undergo cell cycle in conventional 2D culture within 3 days and this can be 
overcome by plating the cells in 3D, but not by growth factors.  However, importantly 
3D culture is not able to reset the proliferative clock when cells have lost this 
capacity after 2D culture. 
Overcoming senescence and generating continuous cellular proliferation are basic 
requirements for cells to grow in culture. This is often achieved by cellular 
immortalisation techniques such as expression of S40 LT Ag or TERT (Counter et al., 
1998). However, immortalisation often disrupts cell cycle regulatory mechanisms so 
is not desirable when wanting the study proliferation in normal cells (Hopfer et al., 
1996). Primary MECs have a very limited proliferation potential which causes 
significant problems for understanding the molecular basis of cell cycle control in 
these cells. Culture conditions of the cells in vitro have been shown to have a 
profound effect on the ability of cells to proliferate (Imagawa et al., 1990; Woodward 
et al., 2000) and our study adds to that body of literature.  We have examined the 
proliferation profile of primary MECs in 2D monolayer culture on collagen I over a 7 
day period (Fig. 1). The primary MECs show a burst of proliferation during the first 48 
hours of culture that subsequently drops to an almost undetectable level. The low 
level of proliferation could not be rescued by addition of growth factors such as 
RANKL and basic-FGF (FGF-2) in primary cells (Fig. 2), or by replating the cells to 
release the contact inhibition (Fig. 3). 
Increasing MEC proliferation 
Several culture models have been developed over recent years to increase the 
proliferation of MECs longer term. Many of these however, use MECs from virgin mice 
in serum free conditions. A serum-free 3D system where MECs from virgin rats were 
cultured with prolactin, EGF, progesterone and hydrocortisone to generate 
proliferation for up to 2 weeks has been described (Darcy et al., 1995a; Darcy et al., 
1995b). The proliferative response of MECs to IGF and EGF and prolactin, has been 
shown to be modulated by the presence of the mammary fat pad (Hovey et al., 
1998). Additional studies with cells from virgin mice and identified regulation by 
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different phospholipids and keratinocyte growth factor (Bandyopadhyay et al., 1988; 
Imagawa et al., 1986; Imagawa et al., 1990). The proliferation of MECs from virgin 
mice was not greater than MECs from pregnant mice in our study (Fig. 1b).  
Co-culturing primary MECs with other cell types is another technique that has also 
been used increase the window of proliferation, for example primary MECs can be co-
cultured with lethally irradiated cells of the immortal LA7 rat mammary tumour line 
(Ehmann et al., 2003), fibroblasts (Gache et al., 1998) or the mammary fat pad 
(Hovey et al., 1998). This however is not a suitable technique to use when MEC 
behaviour is being studied in isolation or when suitable markers are not available to 
distinguish between the cell types allowing the unambiguous identification of the 
epithelial cells within the culture model (Smalley et al., 1998).  However, 
manipulating the matrix dimensionality has not so far been used to modulate the 
proliferative potential of MECs. 
Manipulation of 3D culture environment changes proliferative characteristics 
of MECs 
We have now shown that by culturing MECs in 3D for up to 7 days, allows 
proliferation to be studied in subsequent 2D culture over a longer timeframe. 
Importantly, this now provides a robust system to study cell proliferation after 
manipulating gene expression by recombination or viral transduction (Akhtar et al., 
2009).  
Stromal-epithelial interactions in the mammary gland regulate epithelial growth, 
survival, migration and differentiation (Kass et al., 2007; Streuli and Haslam, 1998). 
When MECs are grown in culture, the micro-environment of the culture dish has a 
vast effect on cellular morphology and function.  For example, primary MECs grown 
in monolayer cannot differentiate, whereas the equivalent cells cultured in a 3D 
environment such as 3D Matrigel or collagen gels are able to differentiate and 
produce milk (Streuli et al., 1991). These differences have been shown to be due to 
ligation of main receptors of the ECM, integrin receptors and their signalling crosstalk 
with growth factors such as EGF and IGF and hormone dependent signalling 
pathways such as prolactin/STAT5 pathway (Lee and Streuli, 1999) rather than 
associated changes in cell shape, morphology (Streuli et al., 1991) and cytoskeleton 
(Zoubiane et al., 2004). 
Proliferation, similarly to differentiation, in MECs is regulated by complex interactions 
between peptide and steroid hormones and growth factors in both epithelial and 
stromal cells. The interaction of MECs with ECM stroma are extremely important in 
mediating the proliferative response, particularly when stimulated by the ovarian 
hormones, estrogen and progesterone (Woodward et al., 1998; Zhang et al., 2002a). 
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Estrogen is a potent stimulator of proliferation in vivo regulating mammary gland 
development during pregnancy (Clarke, 2006), however it has been shown that 
isolated MECs in culture fail to respond to estrogen (Woodward et al., 1998). When 
primary MECs are placed in monolayer culture, they lose expression of ERα and 
growth response to estrogens (Anderson et al., 1998). This loss of ERα expression is 
dependent on the environment as the presence of basement membrane in culture 
partially prevents this decrease in ERα and growth. In particular, it was shown that 
the basement membrane components, collagen IV and laminin I, through α2, α6, β1 
subunits, are critical to ERα expression and its control of proliferation (Novaro et al., 
2003).  
It is possible that when the cells were cultured in 3D Matrigel after isolation, the ERα 
signalling may be maintained for the period it is in 3D Matrigel, therefore retaining its 
ability to proliferate, however when the acini is isolated and replated onto 2D 
monolayer culture, the ERα expression is lost and therefore so is the ability to 
proliferate. Replating the cells back into 3D Matrigel could not stimulate the 
expression of ERα, therefore the ability of the cells to proliferate was not rescued. It 
was purely maintained at the level at the point it was plated into the 3D Matrigel.  It 
will be interesting to determine ERα expression levels during both 2D and 3D culture 
in the future. 
In conclusion, in this study we have further characterised the proliferative behaviour 
of primary epithelial cells in both 2D and 3D culture. We have also developed a new 
method of isolating MEC acini from 3D culture in 3D Matrigel using EDTA, replating 
them onto 2D collagen and the analysing the proliferation. This technique therefore 
enables the study of proliferation in primary MECs as a cell fate in the longer term 
which is required for gene transfer experiments.  
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Figure legends 
Figure 1: Primary mammary epithelial cells (MECs) display a limited window 
of proliferation in conventional 2D culture.  
(a) MECs were isolated from day 16-18 pregnant ICR mice and plated onto collagen I 
coated coverslips in complete media. Proliferation rate was detected using an 8 hour 
EdU pulse on each day for 6 days after isolation. EdU positive nuclei were counted 
blind to quantitate (i) and cells were also co-stained with keratin 5 to detect the 
myoepithelial cells (ii) Scale bars: 13μm. (b) MECs from mid pregnant (mid-grey) 
and 10 week old virgin (light-grey) mice were also isolated and treated as above and 
their proliferation compared to the cells isolated at late pregnancy (black). The 
proliferation at each day after isolation was detected and quantified as percentage on 
EdU positive cells in the whole cell population. Error bars represent SEM. 
Figure 2: The proliferation window of primary MECs cannot be enhanced or 
extended by mammary gland growth factors or different extracellular matrix 
(ECM) proteins.  
(a) MECs isolated from day 16-18 ICR pregnant mice were treated with different 
growth factors 20 nM FGF (i), 100 ng/ml RANKL (ii) and 25 ng/ml Wnt3a (iii) at the 
time of plating for the entire duration of culturing and the proliferation rate 
quantitated by an 8 hour EdU pulse daily over 6 days. (b) The MECs were also plated 
on different ECM proteins (collagen I, laminin, vitronectin, fibronectin) and with no 
ECM proteins present (plastic) and the proliferation rate analysed 4 days after plating 
by an 8 hour EdU pulse.  
Figure 3: The proliferation potential of MECs is largely ablated by replating.   
(a) MECs isolated from day 16-18 pregnant ICR mice were cultured on collagen I for 
2 (i) or 4 (ii) days before trypsinising and replating onto fresh collagen I coated 
plates. The proliferation rate was assessed by an 8 hour EdU pulse daily for four days 
following replating. (b) Cells replated 2 days after isolation were plated onto different 
ECM proteins and the proliferation rate determined 24 hours after replating. (c) Cells 
replated after 2 days of culture were also treated with a variety of growth factors (25 
nM FGF, 100 ng/ml RANKL and 25 ng/ml Wnt3a) and the proliferation rate assessed 
one and two days after replating by an 8 hour EdU pulse. (d) MECs isolated from mid 
pregnant (day 10-12) ICR mice were also isolated and replated after two days and 
their proliferation rate determined by an 8 hour EdU pulse. 
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Figure 4:  3D culture maintains the potential of MECs to proliferate when 
they are subsequently returned to conventional 2D culture.  
(a) Isolated MECs from ICR mice at pregnancy day 16-18, were plated directly into a 
three dimensional laminin rich environment (3D Matrigel).  The cells formed hollow, 
spherical acini and the proliferation rate was assessed using an 8 hour EdU pulse 
over 6 days of culture (b). The EdU positive nuclei were detected and counted. (c) 
The 3D acini can be isolated from the 3D Matrigel using a combination of washing in 
PBS-EDTA to dissolve the 3D Matrigel and centrifugation to recover the acini. The 
complete isolated acini can be replated back onto two-dimensional collagen I. The 
cells proliferate and migrate out forming monolayer was observed through timelapse 
microscopy over 48 hours (d). The proliferation was detected by EdU pulse. Scale 
bar; 50μm (e) and the rate quantitated. The length of time that the cells were 
maintained in 3D culture was varied from 2 to 7 days before the acini were isolated 
and replated onto a 2D culture environment (f).  
Figure 5: 3D culture retains, but does not reset, the ability of cells to 
proliferate subsequently in 2D.  
(a+b+c) Primary MECs were isolated and plated into 2D culture for a differing 
amount of time, before being trypsinised and replated into 3D 3D Matrigel for a 
minimum of 2 days. The acini formed in the 3D culture were isolated using PBS-EDTA 
and subsequently replated back onto 2D culture on collagen I. The proliferation was 
assessed throughout this experiment by an 8 hour EdU pulse every 24 hours of 
culture. 
Supplementary Figure 1: The mammary epithelial cell line MCF10a show the 
same characteristics as primary cells when isolated from 3D 3D Matrigel 
culture by PBS-EDTA.  
MCF10a cells were cultured in 3D Matrigel for 14 days and allowed to form spherical 
acini, which were isolated using PBS-EDTA and replated on tissue culture plastic. The 
cells spread out onto the plastic forming a 2D monolayer. The process was followed 
over time using phase microscopy (a) over 7 days. (b) Cells were fixed 48 hours after 
replating, stained for tubulin (green) to see cell spreading and analysed using 
confocal microscopy. 
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Abstract 
Integrins are required for cell cycle progression in epithelia, but the β-integrin 
subunits involved and the downstream mechanisms are not known. Here we used a 
CreERTM strategy to specifically delete the β1-integrin gene in situ from primary 
cultures of mammary epithelial cells (MECs). This resulted in a block of DNA 
synthesis. Despite the loss of β1-integrins, no changes in cell shape, focal adhesion 
integrity or the ability of the cells to migrate were observed. In β1-integrin null cells, 
β3-integrin was expressed de novo, it associated with core adhesome components, 
and maintained focal adhesion signalling as determined by the presence of phospho-
FAK and phospho-paxillin. β3-integrin adhesions were unable to support Rac 
activation and nuclear translocation of Erk. This study reveals that β1-integrins are 
uniquely required for cell cycle progression in breast epithelia, but not for their 
migration. Thus, the control of epithelial cell fate is dependent on the signalling 
pathways that emanate from specific β-integrin mediated adhesions. 
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Introduction 
Cell cycle progression in metazoan cells is tightly regulated by adhesion to the 
surrounding extracellular matrix (ECM), cell-cell adhesion and by soluble factors. The 
integrin family of adhesion receptors mediate attachment to the ECM, and act as a 
pivotal point in the control of the cell cycle by cooperating with the signalling 
pathways initiated by growth factors (Streuli and Akhtar, 2009). 
Integrins impart numerous controls at both early and (expression of cyclin D and 
down regulation of cell cycle inhibitors) and later stages (M phase and cytokinesis) of 
the cell cycle (Streuli, 2009; Walker and Assoian, 2005). Genetic evidence for a role 
for β1-integrin in proliferation comes from in vivo studies in which chondrocytes, 
skin, hair follicle and mammary gland cells, all of which showed a cell cycle block 
following β1-integrin gene deletion (Aszodi et al., 2003; Brakebusch et al., 2000; Li 
et al., 2005; Raghavan et al., 2000). However the mechanisms by which integrins 
control proliferation is not well understood. It is important to learn precisely how 
integrins control cell cycle because integrin expression and cell cycle regulation are 
both perturbed in proliferative diseases such as breast cancer. 
Most experiments investigating the mechanisms between integrins and proliferation 
have been carried out in fibroblasts and endothelial cells. There is therefore a gap in 
current knowledge of exactly how integrins regulate proliferation in epithelial cells. 
For example, α1-integrin null fibroblasts showed a reduced proliferation rate when 
plated on collagen, thus suggesting that the collagen receptor α1β1 is key in 
regulating cell proliferation (Pozzi et al., 1998). Also in fibrobasts, ligation of integrins 
to the ECM is required for sustained ERK activation, down-regulation of the cell cycle 
inhibitors p21 and p27, Cyclin D1 expression and entry into S-phase (Assoian and 
Schwartz, 2001; Walker and Assoian, 2005). In addition, a role for integrins has also 
been shown in the later stages of the cell cycle including M phase, the formation of 
spindle poles and cytokinesis (Reverte et al., 2006; Taddei et al., 2008; Toyoshima 
and Nishida, 2007). 
Many of these conclusions were arrived at by comparing adherent cells to cells in 
suspension, thereby demonstrating that cell-matrix adhesion is required for efficient 
cell cycle (Aplin et al., 2001; Assoian and Schwartz, 2001). However, cells in 
suspension are not ideal to investigate integrin control because this method does not 
identify which discrete integrin subunit is involved in cell function. Moreover, in 
addition to integrin inactivation, changes in cell shape, the actin cytoskeleton and 
cell-cell adhesion occur in suspended cells. Since an altered cell shape and 
cytoskeleton dramatically affect the cell cycle, these factors need to be kept constant 
in order to study the specific role of integrins (Huang et al., 1998; Ingber et al., 
1995).  
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In this study, we have developed a novel genetic approach to delete the β1-integrin 
gene in situ from primary mammary epithelial cells (MECs). This is achieved by the 
addition of a drug, 4-hydroxytamoxifen (4OHT) to primary cultures of MECs isolated 
from bi-transgenic Itgβ1fx/fx;CreER™ mice. We report that in situ deletion of β1-
integrin in MECs leads to a block in the cell cycle at G1/S, coinciding with both Rac 
inactivation and an inhibition of ERK translocation to the nucleus. Importantly, we 
find that β3-integrin is up-regulated in the β1-integrin null cells and these cells are 
still able to spread and migrate, indicating that the block in cell cycle is β-integrin 
subunit specific. In addition, the core adhesome proteins recruited to β1 adhesions 
are the same as those in de novo β3 adhesions, indicating the presence of novel 
mechanisms linking β1-integrin with the cell cycle machinery. We therefore conclude 
that cell fate is integrin subunit specific, with β1-integrin being required for cell 
proliferation but not migration. 
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Materials and Methods 
Mouse strains and breeding 
The Itgβ1fx/fx and CreER™ mouse lines (Danielian et al., 1998; Graus-Porta et al., 
2001) were crossed to produce the Itgβ1fx/fx;CreERTM mouse line. The CreER™ mouse 
contains a transgene that encodes Cre-recombinase fused to a mutated ligand 
binding domain of the estrogen receptor that specifically binds 4-hydroxytamoxifen 
(4OHT) (Supp. Fig. 1). CreER™ is under the control of the chicken β-actin promoter 
(Danielian et al., 1998). The Cre-recombinase is maintained in the cytosol by binding 
hsp90. Upon addition of 4OHT to the cell culture medium, hsp90 is released, Cre 
translocates to the nucleus and deletes the floxed gene of choice. Cre-mediated 
deletion of β1-integrin in MECs was achieved by harvesting the MECs from 
Itgβ1fx/fx;CreERTM mice and treating with 100 nM 4OHT. Genotyping was performed as 
previously described using DNA prepared from ear punches (Danielian et al., 1998; 
Graus-Porta et al., 2001). 
Primary Cell Culture 
Primary mammary epithelial cells were isolated from 15.5- to 17.5-d pregnant 
β1Itgfx/fx;CreER™ or wildtype ICR mice and cultured on collagen I or vitronectin - 
coated dishes, or in Matrigel, as described (Pullan et al., 1996). Cells were grown in 
full growth medium containing 5 μg/ml insulin, 1 μg/ml hydrocortisone, 3 ng/ml EGF, 
10% FCS, 50 U/ml Pen/Strep, 0.25 μg/ml fungizone, and 50 μg/ml gentamycin in 
Hams F12 medium. Replating experiments were performed usually after 48 h growth 
on collagen. To replate, the growth medium was removed, and cells were incubated 
for 1 minute in HE buffer (9.5 g/L HBSS-Ca2+ free, 0.35 g/L NaCO3, and 2 g/L EDTA; 
Sigma-Aldrich) before trypsinising (GIBCO BRL) for 2–3 min, spinning at 12,000 rpm 
for 4 min, and plating onto collagen I. 
Genomic DNA PCR 
Genomic DNA was isolated from control and 4OHT treated MECs at various timepoints 
following 4OHT addition and analysed by PCR. Extraction of DNA involved digestion of 
the cells with 10 μg/ml proteinase K and isopropanol precipitation of DNA before 
setting up the PCR reaction. The position of the PCR primers for the β1 gene is shown 
in Fig. 1 and PCR was carried out as described (Graus-Porta et al., 2001). The PCR 
reaction products were 2.1 kB (β1 flox) and 1.3 kB (β1 flox recombined and β1 null). 
Isolation of mammary gland acini from Matrigel and migration analysis 
Detailed methods are provided in Jeanes et al, submitted manuscript, 2010. Briefly, 
control and 4OHT treated MECs were plated into Matrigel (BD Biosciences) directly 
after isolation and cultured for a minimum of 48 hours. Cells were washed, scraped 
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off the dish in freshly prepared sterile PBS/5 mM EDTA and transferred to a clean 
falcon tube, kept at 4oC for 5 minutes. The cells were spun down at 42xg for 
3 minutes and the cells resuspended in fresh PBS/EDTA and incubated on ice for 5 
minutes. This was repeated twice. To remove the residual EDTA, the cells were 
washed once and resuspended in the final volume of medium. The cells were then 
replated onto pre-coated collagen I plates. The process of the cells migrating out 
from the isolated acini was followed using an AS MDW live cell imaging system 
(Leica) over a 72 hour time period. The tracks were generated and point to point 
measurements were made using the ImageJ plugin, MTrackJ (Fig. 1c). The ImageJ 
plugin, Chemotaxis Tool, was used for the generation of chemotaxis plots. MECs were 
also plated onto collagen I coated coverslips and fixed at certain timepoints for 
immunostaining.  
Immunoblotting Analysis 
Protein was extracted from cells using 1x NET buffer (50 mM Tris-Cl, 150 mM NaCl, 
1% NP-40, and 2 mM EDTA, pH 7.6) supplemented with 1 mM sodium 
orthavanadate, 10 mM sodium fluoride, and 1:100 dilution of Protease cocktail 
inhibitor set 1 (Calbiochem). Equivalent amounts of protein were determined by 
quantification using a BCA protein assay (Bio-Rad Laboratories) to ensure equal 
loading of proteins. Cell lysates were subjected to SDS-PAGE then transferred to 
nitrocellulose membranes, which were blocked in 5% milk solids and then incubated 
overnight at 4oC with specific primary antibodies. The membranes were incubated 
with the HRP-conjugated secondary antibodies (Jackson Laboratories) and signals 
detected by enhanced chemiluminescence reagent (ECL: Pierce) or IR conjugated 
antibodies for detection on the Odyssey system (Li-cor). Primary antibodies were as 
follows: β1 integrin (BD Transduction #553715), hsp70 (ABR #MA3-028) , vinculin 
(Sigma #V4505), ILK (Chemicon #AB3812), phospho-FAK (pY397) (Invitrogen #44-
624), phospho-FAK (pY577) (Invitrogen #44-625), FAK (BD Biosciences #610088), 
phospho-paxillin (pY118) (Biosource #44-72), paxillin (BD Biosciences #610052), 
calnexin (Bioquote #SPC-108A/B), β3-integrin (Cell Signalling #4702), cyclin D1 
(Abcam #ab7958), phospho-GSK3β (Ser9) (Cell Signalling #9336), GSK3β (Sigma 
#H1009), phospho-Akt (Ser473) (Cell Signalling #9271), Akt (Cell Signalling 
#9272), phospho-ERK (Cell Signalling #9101), ERK (Santa Cruz #Sc-154), phospho-
ELK-1(Santa Cruz #Sc-7979), Rac (upstate #05-389), phospho-PAK1 (Cell Signalling 
#2605), Cre-recombinase (Chemicon #mAb3120), and tubulin (Sigma #T0198). 
Proliferation Assay and Immunostaining 
Primary MECs were pulsed with 10 μM EdU, added to culture medium, for 8 hours to 
measure the proportion of primary MEC culture undergoing DNA synthesis at 
different time points. This time of EdU addition was chosen empirically because these 
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cells cycle very slowly and the amount of EdU (or BrdU) incorporated over a 2 hour 
time frame was too low to measure reliably. Visualisation of EdU labelled nuclei was 
carried out using EdU-Click reaction according to manufacturer’s instructions (Click-
iT™ EdU Alexa Fluor® 488 Imaging Kit # C10083 from Invitrogen). Expression and 
distribution of various proteins were visualized by indirect immunofluorescence. 48 
hours after plating onto collagen I coated glass coverslips, cells were fixed for 10 min 
in PBS/4% (wt/vol) paraformaldehyde (PFA) and permeabilized for 5 min using 
PBS/0.2% (vol/vol) Triton X-100. Nonspecific sites were blocked with PBS/10% goat 
serum (for 1 h at RT) before incubation with antibodies diluted in PBS/5% goat 
serum (for 1 h at RT each). F-actin was detected by incubating cells with Texas red 
phalloidin (Invitrogen) for 1 h at RT, whereas nuclei were stained using 4 μg/ml 
Hoechst 33258 (Sigma-Aldrich) for 2 min at RT. Cells were washed in PBS before 
mounting in prolong antifade (Invitrogen). Immunostained cells were visualized with 
an Axioplan2 microscope (Carl Zeiss MicroImaging, Inc.). 
Images were captured with a digital camera (Orca ER; Hamamatsu) and processed in 
Openlab software (Improvision) and Adobe Photoshop. The EdU-positive cells were 
counted blind and the number of EdU labelled nuclei calculated as a percentage of 
the total DAPI stained nuclei. An average of 2000 cells were counted per experiment 
for a minimum of 3 independent experiments. Primary antibodies were as follows if 
different from the ones used for western blotting: β1-integrin (Chemicon 
#MAB1997), phospho-histone H3 (Ser10) (3H10) (Upstate #05-806), β3-integrin 
(2C9.G2 (HMß3-1)(Biolegend #104311), mouse fibronectin (Millipore #AB2033). 
Alexa-fluor conjugated secondary antibodies were purchased from Invitrogen. 
Real-time reverse transcription-polymerase chain reaction (RT-PCR) 
Total RNA was extracted using the Trizol (Invitrogen) following the manufacturer’s 
instructions. First-strand cDNA was synthesized from 1 µg of total RNA using the 
Revertaid cDNA synethesis Kit (Fermentas) as described by the manufacturer. Gene 
expression was measured using the TaqMan Gene expression Mastermix (part 
number 4369514) and the StepOnePlus qPCR machine (Applied Biosystems) 
according to the manufacturer’s instructions. TaqMan gene expression assay primer 
probe sets for each gene were used. The Gene Assay IDs of the TaqMan gene 
expression assay supplied by Applied Biosystems were Mm01253233_m1 for β1 
integrin, Mm00443972_m1 for β3-integrin, Mm01266844_m1 for β4 integrin, 
Mm00439825_m1 for β5 integrin, Mm00445326_m1 for β6 and 4352932E for 
GAPDH. The calibration samples were control untreated cells, and GAPDH was used 
as an endogenous control. 
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Adhesion Assay 
Control and β1-integrin null MECs were used to perform the adhesion assay as 
follows. 4 x 104 cells were plated in 96 well dishes pre-coated with collagen I and 
fibronectin (25μg/ml; Sigma) in the presence or absence of 10 μg/ml β1-integrin 
function blocking antibody (Klinowska et al., 1999) and the β3-integrin function 
blocking antibody (2C9.G2) . After 1h, the unattached cells were washed away and 
adhered cells were fixed and stained with crystal violet, solubilised in 1% SDS and 
the absorbance read at 595nm. Each time point was assayed in triplicate and the 
experiment performed 3 times. 
Assay for the activity of endogenous Rac 
Cells cultured on collagen I were rapidly scraped and lysed into 1× NP-40 lysis buffer 
and centrifuged at 17500 x g for 15 min at 4°C. 25 μg of GST-PAK PBD coupled to 
glutathione agarose beads (Calbiochem) was used to precipitate GTP-bound Rac from 
cell lysates for 40 min at 4°C. Active Rac was detected by immunoblotting with an 
anti-Rac antibody and quantified using the Odyssey System from Li-Cor. Parallel 
samples were blotted for the presence of total Rac. 
Statistics 
Statistical analysis was carried out using one way ANOVA to determine significance 
and a tukeys or bonferroni’s post-hoc test to examine individual differences.  A paired 
student t-test to determine significance where there was only one variable.  Where 
significance is indicated *** is p<0.001, ** is p<0.01 and * is p<0.05. 
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Results and Discussion 
β1-integrin deletion in MECs reveals a specific role for β1-integrin in cell 
cycle but not migration. 
By removing β1-integrin genetically in situ, we present evidence that β1-integrin 
provides unique signals that are required for epithelial cell cycle. A MEC culture 
system was generated whereby the β1-integrin gene could be removed in situ. In 
MECs from Itgβ1fx/fx;CreERTM mice, the addition of 100 nM 4-hydroxytamixofen 
(4OHT) to the cell culture medium deleted the β1-integrin gene within 24 hours 
(Supp. Fig. 1), with the loss of the β1-integrin protein being confirmed by western 
blot analysis (Fig. 1a). The multiple bands for β1 integrin show the surface 
glycosylated integrin and the unglycosylated newly synthesised protein (Bellis, 
2004). 
An essential advantage of using the CreER system is that the β1-integrin gene is 
deleted without the need to replate the MECs. In situ deletion allows the 
consequences of the loss of β1-integrin in focal adhesions to be investigated without 
the other changes that occur in suspension cells or after replating, such as 
rearrangement of the actin cytoskeleton, changes in cell-cell interactions, and any 
effects of trypsin. This enables key conclusions to be made about integrin-specific 
events in the control of proliferation. 
The proliferation of primary MECs from Itgβ1fx/fx;CreERTM mice was assessed at 
various stages of culture using EdU (Buck SB et al., 2008) (Fig. 1b). In 4OHT treated 
cells, β1-integrin was deleted and there was a significant decrease in the number of 
EdU positive nuclei in β1-integrin null cells compared with controls, suggesting a 
G1/S block in cell cycle (Fig. 1c). The inhibition of proliferation following the deletion 
of β1-integrin was evident up to 4 days of culture, after which cells lose their 
competence to proliferate (Jeanes et al, submitted). MECs isolated from the CreERTM–
only mice showed no change in proliferation between control and 4OHT treated 
MECs, indicating that the proliferation defect in Itgβ1fx/fx;CreERTM cells was not due to 
Cre-activation or the presence of 4OHT, but only the loss of β1-integrin (Supp. 
Fig. 2a). 
Although proliferation defects have been described in β1-integrin knock out in vivo 
studies in tissues such as chondrocytes, skin and the hair follicle, these reports did 
not investigate a signalling mechanism (Aszodi et al., 2003; Brakebusch et al., 2000; 
Raghavan et al., 2000). In the mammary gland, the proliferation block following 
deletion of β1-integrin is due to the up-regulation of the cell cycle inhibitor p21(cip1), 
however the proximal signals linking integrin deletion to cell cycle arrest are not 
known (Li et al., 2005). By using EdU, which is incorporated into the DNA during S 
86 
 
phase, we have now found that β1-integrin is required for proliferation in MECs and 
that deletion of the β1-integrin gene deletion causes a G1/S block in cell cycle.  
To determine if the removal of β1-integrin has widespread effects on MEC behaviour, 
we investigated whether this alters another integrin-dependent process, cell 
migration. We analysed the 2D movement of MECs replated onto native collagen-I. 
Here, multicellular MEC acini were cultured on Matrigel for long enough for the β1-
integrin gene to be deleted, and then either WT or β1-integrin null acini were isolated 
using EDTA and plated onto collagen-I, on which the cells collectively migrated to 
form sheets (Supp. Fig. 3a; Jeanes et al, ibid). Since β1-integrin containing cells 
proliferate as well as migrate (Supp. Fig. 3b), the experiments were performed in the 
presence of Mitomycin C (Supp. Fig. 3c). The migration tracks of the MECs (at the 
edge of the cell colony that are part of the cohesive monolayer) were captured using 
timelapse microscopy and analysed (Fig. 1d). The average speed of the control and 
β1-null MECs were not significantly different, therefore showing that the loss of β1 
integrin does not affect the ability of the cell to migrate (Fig. 1e i). 
Integrins are critical in cell migration, providing traction and acting as 
mechanosensors (Brakebusch and Fassler, 2005). The individual role of different β-
integrin subunits in cellular migration is beginning to be unravelled in fibroblasts, 
where it has been discovered that endocytosis of surface integrins and vesicle 
trafficking provide key mechanisms of migration control (Caswell et al., 2009). 
Directional migration or random cellular movement depends on different methods of 
endocytic recycling of αvβ3 and α5β1 integrins, however an alternative mechanism 
may be used in epithelial cell migration because they move as cellular sheets rather 
than individual cells with lamellaepodia and fillopodia (White et al., 2007). 
Our results demonstrate that β1-integrin is not required for the collective migration 
of MECs on 2D collagen substrata. The β1-integrin containing cells contain α2β1-
integrin, which permit adhesion to collagen-I, migration and cell cycle. In the 
absence of β1 integrin, MECs are still able to migrate but experience a proliferation 
block.  
The conclusion from these results is that β1-integrin is required for cell cycle 
progression in MECs, but not for other cell fates such as migration. We next aimed to 
understand the mechanism underlying this integrin specificity of signalling. 
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Loss of β1-integrin does not affect focal adhesion integrity, cytoskeletal 
organisation or cell shape 
Both β1-containing and β1-null MECs were able to migrate, indicating the presence of 
functional ECM interactions under both conditions. Focal adhesions were identified by 
the presence of their major structural components including vinculin, talin and 
paxillin. Moreover, there were no major differences between control and β1-integrin 
null cells in the intensity and distribution of these proteins (Fig. 2a). Western blotting 
analysis indicated that neither the total levels of vinculin, Integrin-linked kinase 
(ILK), Focal adhesion kinase (FAK) and paxillin, nor their signalling capacity 
(phosphorylation status of FAK and paxillin), were altered after integrin deletion 
(Fig. 2b+c, CreER control in Supp. Fig. 2b). In addition, β1-null MECs had a similar 
shape to WT MECs by phase contrast microscopy and there were no discernable 
differences in their microfilament and microtubule cytoskeletons (Supp. Fig. 4) 
Together, these results suggest that another integrin is expressed in the primary 
MECs to compensate for the loss of β1 integrin, thereby allowing the β1-integrin null 
cells to adhere to the ECM, form functional focal adhesions and to continue signalling 
though FAK and paxillin. Importantly, any integrin expressed in the absence of the β1 
subunit permits focal adhesion assembly, spreading and 2D migration, but will not 
support proliferation. 
 
β3-integrin replaces β1-integrin in focal adhesions as the functional integrin 
in β1 null MECs 
To identify compensatory integrins, RT-PCR was performed for a range of β integrin 
subunits with RNA isolated from control and β1-null cells 48-h after 4OHT treatment 
(Fig. 3a). There was a 2-fold increase in β3-integrin expression in the β1-null cells, 
but no major changes in other β integrin subunits were observed. The increase in β3-
integrin mRNA expression was reflected at the protein level (Fig. 3b). 
Immunofluorescence staining revealed β3-integrin within focal adhesions, in place of 
the β1 subunit (Fig. 3c). β3-integrin was also seen in place of β1-integrin in the MEC 
acini isolated from Matrigel spreading out into 2D monolayer culture (Supp. Fig. 3d). 
β3-integrin, in contrast to β1, has a limited cellular and tissue distribution, and is not 
often expressed in epithelial tissues. β3-integrin binds to RGD ECM proteins VN, 
fibronectin (FN), fibrinogen, and thrombospondin (Gilcrease, 2007). Its expression 
and activity is tightly regulated during a variety of biological processes including 
wound healing (Graber et al., 1999), angiogenesis (Rupp and Little, 2001), tumour 
progression and metastasis (Sheldrake and Patterson, 2009), and particularly breast 
cancer (Anderson et al., 2009; Sloan et al., 2006).  
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To further investigate β1/β3 expression in MECs, we examined cells cultured on 
different substrata. WT MECs cultured on collagen-I contained β1- but not β3-
integrin. In contrast, β1-null cells (i.e. 4OHT-treated) only expressed β3-integrin 
(Fig. 3d). However, in cells plated onto FN (a β3 ligand), both β3 and β1-integrin 
were present in WT MECs, while only β3-integrin was present in the β1 null cells 
(Fig. 3e). In addition, β3 expression was not seen in the control 4OHT-treated 
CreERTM only MECs (Supp. Fig. 2c).  
These results suggest that the major β-integrins present in focal adhesions are 
dependent on the ligand available. We therefore examined the adhesion 
characteristics of MECs in the absence of β1 integrin. An adhesion assay revealed 
that β1-null cells had poor adhesion to collagen-I but could adhere to FN, which is a 
β3 ligand (Fig. 3f). Moreover, mouse-FN was present in the ECM of β1-null MECs 
plated onto collagen I (Fig. 3g). This indicates that FN deposited by the β1-null MECs 
enables them to adhere using β3-integrin receptors. Deposited mouse-FN was also 
present in the ECM of WT cells, but at lower levels than β1-null MECs (Fig. 3g). Thus, 
MEC focal adhesions contain β3-integrin in the absence of the β1 subunit, and are 
able to adhere to secreted FN. We have previously shown that both ECM and integrin 
transcription is ECM dependent (Delcommenne and Streuli, 1995; Streuli and Bissell, 
1990). Our new results demonstrate that the major integrin receptors of MECs can be 
altered according to availability of specific integrin subunits, and also that the ECM 
matrix is modified accordingly to ensure optimum adhesion.  
In support of this paradigm, high expression levels of β3-integrin occur in β1-null 
fibroblasts, and re-expression of β1-integrin in these cells resulted in down-regulation 
of the β3-subunit (Retta et al., 2001). Modification of integrin ratios also occurs in 
response to changes in extracellular environment and available ligand during tissue 
formation or repair. For example, αvβ3 is increased during wound repair, correlating 
with an up-regulation of FN and VN at the wound site (Feng et al., 1999). 
 
Cell cycle arrest in β1 null cells is due to decreased Rac activation and a 
block in ERK translocation to the nucleus 
The β1-null MECs are unable to undergo cell proliferation unlike the control β1-
positive cells, despite the up-regulation and presence of β3-integrin in focal 
adhesions. This indicates that there are different signalling mechanisms involved in 
cell cycle regulation between β1- and β3-integrin. Following β1-integrin deletion, cells 
cultured on collagen showed no difference in FAK and the core adhesion complex 
proteins, suggesting that the differential ability of β1- and β3-integrin to control the-
cell cycle machinery might be reflected in altered downstream signalling pathways. 
89 
 
The GTPase Rac has been shown to regulate proliferation by interacting with many 
different signalling pathways (Welsh, 2004). To examine if there were any differences 
in Rac activity between control and β1 null cells, a Rac activity assay was carried out 
on cells at the peak of their proliferation. WT MECs contained high levels of active 
Rac, which was significantly decreased in β1-deleted cells (Fig. 4a). Consistent with 
these results, we also observed a reduction in the phosphorylation of the downstream 
effector kinase PAK1 (p21-activated kinase) (Fig. 4b). 
To determine whether Rac could be the link between the specific β integrin subunit 
and proliferation, WT MECs were treated with the Rac inhibitor NSC23766. The rate 
of proliferation was assessed by EdU incorporation, and found to be significantly 
decreased in Rac-inhibited cells (Fig. 4ci). Thus, Rac has an important role in 
proliferation control of MECs.  
Signalling through Rac and PAK is directly involved with the regulation of the MAP 
Kinase phosphorylation cascade (Eblen et al., 2002; Slack-Davis et al., 2003). We 
therefore examined whether β1-integrin deletion might alter cell cycle by interfering 
with ERK activation. Analysis of phospho-ERK in steady state conditions in lysates of 
control and β1-null MECs during the 2-3 days of primary cell culture in which 
proliferation is at the highest levels, did not reveal any differences in its 
phosphorylation (Fig. 4di). In addition, there was no change in ERK phosphorylation 
between control and β1-null cells following a 30-min serum stimulation (Fig. 4dii). 
However, active ERK was required for cell cycle, as treatment of WT MECs with the 
ERK inhibitor U0126 inhibits proliferation (Fig. 4cii). 
ERKs (ERK1/2) reside primarily in the cytoplasm and upon phosphorylation and 
activation, ERK translocates from cytoplasm to the nucleus. Nuclear translocation of 
ERK is required for cell cycle entry due to the ERK-dependent phosphorylation of 
target transcription factors such as ELK-1 (ETS (E twenty six)–like kinase 1) (Brunet 
et al., 1999). We therefore examined the localisation of phospho-ERK (pERK) in 
control and β1 null cells. This revealed that ~20% of WT MECs contained nuclear 
pErk, corresponding to the 20-25% cells in S-phase at any one time (Fig. 1c). 
However in contrast, nuclear pERK was dramatically reduced in the β1-null cells 
(Fig. 4e). In addition, the phosphorylation of ELK1 was decreased in β1-null MECs 
compared to controls (Fig. 4dii). Thus, the translocation of pERK into the nucleus to 
stimulate S-phase is dependent on specific β-integrin subunits. In the absence of β1-
integrin, when β3-integrin is present, pERK is unable to translocate into the nucleus, 
phosphorylate ELK-1 and stimulate proliferation. 
Together, our data reveal that β1-integrin uniquely signals to regulate ERK 
translocation and that this is directly linked to cell cycle progression. The mechanism 
is probably through a decrease in Rac activity and ERK translocation to the nucleus. A 
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rescue proliferation experiment with active V12 Rac in the β1 null MECs would further 
support this suggested mechanism.  Importantly, and in contrast to studies on 
fibroblasts, integrin signalling does not impact on ERK phosphorylation, but rather its 
nuclear translocation. Previous reports have shown that adhesion to different ECM 
proteins (FN and laminin) elicits altered proliferative responses through changes in 
Rac activity, indicating that it is a crucial mediator in the control of cell cycle through 
integrins (Mettouchi et al., 2001). Rac is also involved in the assembly of MAPK 
signalling complex which is activated through integrin engagement, and is therefore a 
key point in integrating adhesion and growth factor signals (del Pozo et al., 2000; 
Eblen et al., 2002; Slack-Davis et al., 2003). Our results extend those data by 
showing β-integrin specific control of cell cycle, via activation of Rac, in identical cells 
that have been altered in situ by the deletion of a single integrin subunit. 
Interestingly Rac is also responsible for nuclear localisation of Stat proteins through 
mgcRacGAP which chaperones these to nucleus (Kawashima et al., 2009). 
ERK lacks a nuclear localisation sequence, and there are two proposed mechanisms 
that explain how ERK is transported across nuclear membrane. One possibility is that 
ERK translocation occurs in an energy independent process via direct binding to 
nucleoporins (Yazicioglu et al., 2007). ERK localization may also be dictated by other 
proteins that ERK binds to (Lidke et al., 2010), as well as MKP-7, the JNK 
phosphatase (Masuda et al., 2010). Regulatory proteins such as MKP-7 could be the 
key adapters that differentiate between β1- and β3-integrin signalling. Interestingly, 
MECs have lower rates of ERK translocation than transformed breast cell lines due to 
decreased levels of nuclear pore proteins and transport factors, and these may also 
be differentially expressed in β1- vs β3-expressing MECs (Smith et al., 2010).  
A comparison between adherent and suspension fibroblasts has shown that adhesion 
regulates ERK translocation and the transcription of genes required for S-phase 
(Aplin, 2003; Aplin et al., 2002; Aplin et al., 2001). Under these conditions, the 
changes identified could be due to altered cell shape, focal adhesion signalling and 
cytoskeleton integrity. Our results extend those data by showing that in cells deleted 
of β1-integrin in situ, with the same shape, cytoskeleton, and similar adhesion 
complexe proteins, also have altered ERK function. In addition, a β1-integrin C’-
terminal tail mutant in fibroblasts displayed defective ERK nuclear translocation, 
though β3-integrins were not examined in this case (Hirsch et al., 2002). Thus our 
results provide genetic evidence that specific β-integrins directly control ERK nuclear 
translocation, and moreover that there is a β-integrin control over cell cycle in 
epithelia as well as other cell types. 
 
 
91 
 
Summary 
We show that the regulation of epithelial cell fate by integrins is dependent on the 
presence of specific integrin subunits that activate particular signalling pathways. β1-
integrin adhesion complexes must contain specific proteins that enable them to signal 
to control proliferation, however these proteins remain to be identified. Suggested 
differences could be in the recruitment of a specific GEF, which would explain the 
difference in Rac activation. We are currently defining such differences using a 
proteomics approach.  
We conclude that specific β-integrin adhesions determine cell-fate responses, and 
that β1 integrins are uniquely required for cell cycle progression, but not for 
migration in breast epithelia. 
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Figure Legends 
 
Fig. 1: β1-integrin null MECs display a proliferation block but show similar 
ability to migrate compared to control cells.  
(a) Primary MECs from β1fx/fx; CreERTM were cultured on collagen-I in the presence or 
absence of 4OHT. β1-integrin deletion was always verified by western blotting. 
(b+c) Cells were treated with an EdU pulse at Day 2, 3, 4 and 5 after isolation, fixed 
and stained using EdU-Click reaction and β1-integrin antibody. The proliferation rate 
was quantified by counting the percentage of EdU positive nuclei compared to total 
number of cells. Approximately 1000 cells were counted per experiment and a 
minimum of 3 independent experiments was carried out. The error bars are ± 
SEM and statistical significant determined by a one way ANOVA where *** p<0.001 
and ** p<0.1 (c). Representative images of Day 4 are shown (b).  
(d+e) Acini formed by control and β1-null MECs in Matrigel were isolated using 
EDTA/PBS and replated onto collagen I coated plates. The acini settled down onto the 
collagen-coated surface and spread out forming a monolayer (see Suppl Fig 3). Cells 
were treated with 10 μM Mitomycin C for 30 minutes prior to timelapse capture to 
inhibit the proliferation. The tracks of individual cells were followed (d) and the 
average speed (ei) calculated.  
Scale bars: –38 μm. 
 
Fig. 2: β1-integrin null MECs show no significant changes to focal adhesions.  
(a) Primary MECs were treated with 100nM 4OHT at the time of isolation, cultured on 
collagen I coverslips, fixed 72 hours after isolation, and stained for focal adhesion 
proteins; vinculin, talin and paxillin.  
(b) Western blotting analysis of cell lysates from primary MECs cultured for 3 and 4 
days and probed for the indicated antigens. Calnexin was used a loading control.  
(c) Immunofluorescent staining of phospho-Paxillin (pY118), phospho-FAK (pY397), 
phospho-Paxillin (pY31) in control and 4OHT treated β1 null primary MECs fixed 3 
days after isolation.  
Scale bars: –20 μm. 
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Fig. 3: β1-integrin deletion induces a switch to β3-integrin focal adhesions.  
(a) RT-PCR analysis on RNA from control and β1 null MECs 3 days after isolation, to 
analyse the levels of β1, β3, β4, β5 and β6 integrin.  
(b) Western blotting analysis of cell lysates from primary MECs cultured for 2 days 
and probed for β1-integrin and β3-integrin. Calnexin was used as a loading control.  
(c) Primary control and 4OHT treated β1 null MECs were cultured on collagen I 
coated coverslips for 3 days before fixing and staining with β1 and β3-integrin 
antibodies.  
(d+e) WT and 4OHT treated primary MECs were plated on collagen I (d) and FN (e) 
coated coverslips, fixed 3 days after isolation and stained for β3-integrin (green) and 
β1-integrin (orange).  
(f) Primary MECs cultured with and without 4OHT for 3 days were isolated and used 
for an adhesion assay in serum free media on both collagen I and fibronectin in the 
presence of β1-integrin and β3-integrin function blocking antibodies (10 μg/ml). 
Three independent experiments were performed with a representative graph shown. 
The error bars represent standard deviation of the mean of triplicate samples within 
one experiment.  
(g) WT and 4OHT treated primary cells plated onto collagen I coverslips were also 
stained for mouse FN.  
Scale bars: –20 μm. 
 
Fig. 4: Deletion of β1-integrin induces loss of Rac activation and block in 
translocation of phospho-ERK to the nucleus.  
(a) Rac activity was analysed using recombinant GST–Pak-binding domain (PBD) in 
pull-down assays of lysates from control and 4OHT treated β1 null MECs both 2 and 3 
days after isolation (i). Levels of β1-integrin and total Rac were assessed on the 
same lysates to ensure β1-integrin knock down and correct loading. Quantification of 
the bands took places using the Li-cor Odyssey system and the relative levels of Rac 
activity was plotted (ii).  
(b) Cell lysates were isolated at day 2 from both control and β1-integrin null MECs 
and the levels of phospho-PAK1, total Rac and β1-integrin were assessed by western 
blotting. Calnexin was used as a loading control.  
(c) WT MECs from ICR mice were isolated and cultured for 24 hours before treating 
with 100 μM Rac inhibitor for 20 hours (i) and 1 μM of ERK inhibitor U0126 for 24 
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hours ii), before assessing the percentage of EdU positive cells. The equivalent 
volume of DMSO was used as a control.  
(d) Cell lysates were harvested from control and 4OHT treated β1 null MECs in steady 
state conditions 2 and 3 days after isolation and were analysed by western blotting 
for β1 integrin, phospho-ERK and total ERK (i). Control and β1 null MECs cultured for 
2 days after isolation were serum starved for 12 hours and subsequently stimulated 
with full media for 30 minutes before lysing and analysing the protein levels of β1 
integrin, phospho-ERK, total ERK and phospho-elk1 by western blotting (ii).  
(e) Cells cultured on collagen coated coverslips in steady state conditions as 
described above were fixed 2 days after isolation and stained for β1-integrin (red), 
phospho-ERK (green) (i). The white arrow highlights the localisation of phospho-ERK 
outside the nucleus in β1-integrin null cells and phospho-ERK inside the nucleus of 
control cells. The percentage of nuclear phospho-ERK was counted by blind counting 
and quantified (ii).  
Scale bar: 30 μm 
Supp. Fig. 1: CreER deletion of β1-integrin in MECs.  
(a) Schematic diagram of the CreERTM transgene (i) and β1-integrin allele before and 
after treatment with 4OHT (ii).  
(b) Control (non-treated) and β1-integrin null (4OHT treated at time of isolation) 
primary MECs were fixed and immunofluorescently stained for β1-integrin (red) and 
Cre-recombinase (green) to show loss of β1-integrin and localisation of Cre-
recombinase in the nucleus.  
(c) Genomic DNA was isolated over a timecourse of 24 hours from control and 4OHT 
treated primary MECs. PCR analysis was a carried out to show the Cre-mediated 
recombination on genomic DNA and deletion of the β1-integrin gene. The 2.1 kB 
product represents the full-length floxed allele and the 1.3 kB represents the 
recombined allele.  
Scale bars: –20 μm. 
Supp. Fig. 2: Control experiments using CreERTM.  
MECs were isolated from CreERTM-only mice, treated with 4OHT, and analysed as a 
control.  
(a) The proliferation of control (black bars) and 4OHT treated (grey bars) CreER 
MECs was analysed by EdU, 2, 3 and 4 days after isolation.  
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(b) Cell lysates from primary CreERTM-only MECs and MECs replated onto collagen I 
were analysed using western blotting. The proteins levels were assessed for β1 
integrin, phospho-FAK (Tyr397), phospho-FAK (Tyr577), ERK and Cre-recombinase.  
(c) The localisation of Cre, β1-integrin (i) and β3-integrin (ii) was investigated by 
immunofluorescent staining in primary CreERTM-only MECs. 
Scale bars: ci – 10 μm, cii – 20 μm. 
Supp. Fig. 3: Spreading of WT and β1-integrin-null MECS after replating 3D 
acini to 2D substrata.  
In these experiments, control and β1 null MECs were plated directly into 3D Matrigel 
for 72 hours before isolating the acini with EDTA/PBS and replating onto 2D collagen 
I coated plates. The acini were allowed to settle, attach, proliferate and migrate to 
spread out onto the surface.  
(a) Timelapse microscopy was used to examine the migration of MECs on the 
collagen coated dishes (i). The total area spread by the MECs was calculated using 
ImageJ (ii). This experiment was done in the absence of mitomycin C 
(b) The proliferation of the cells spreading out onto the 2D collagen from (a) was 
assessed using an EdU pulse along with staining of β1 integrin.  
(c) The cells were treated with 10μM mitomycin C for 30 minutes prior to timelapse 
capture to inhibit the proliferation. The area spread was measured and shown to be 
similar in WT controls to β1-integrin-null cells when proliferation was blocked.  
(d) The proliferation was assessed using an EdU pulse and the cells fixed 3 days after 
replating and stained for β1-integrin (red), β3-integrin (green).  
Scale bars: 40μm 
Supp Fig 4: Cell shape and cytoskeleton in control and β1 null MECs 
(a) Primary MECs were treated with 4OHT and cultured on collagen I coverslips and 
the cell morphology observed by phase microscopy.  
(b) The cells were fixed 72 hours after isolation and stained for β1 integrin (green) 
and the cytoskeletal proteins actin and tubulin (red).   
Scale bars: a–50 μm, b-20 μm. 
101 
 
 
 
 
Figure 1 
 
 
102 
 
 
 
 
 
 
Figure 2  
103 
 
Figure 3 
 
 
104 
 
Figure 4 
 
 
 
105 
 
 
 
 
 
Supplementary Figure 1 
  
106 
 
 
Supplementary Figure 2 
107 
 
 
Supplementary Figure 3 
108 
 
 
Supplementary Figure 4 
 
109 
 
 
 
 
 
 
 
 
 
Chapter 4: β1 integrins in a breast cancer 
progression cell line model 
 
 
  
110 
 
 
β1 integrin in a breast cancer progression cell line model 
 
AI Jeanes, L Rinaldi, CH Jameson, FM Foster, CH Streuli. 
 
Wellcome Trust Centre for Cell Matrix Research, Faculty of Life Sciences, University of 
Manchester, Michael Smith Building, Oxford Road, Manchester M13 9PT 
 
 
 
Corresponding Author: 
Fiona Foster, email: fiona.foster@manchester.ac.uk, tel: +44 161 2755556 
 
 
 
Condensed title: β1-integrins in MCF10a progression model 
 
Character count: 42,778 
  
111 
 
 
Abstract 
Disorganised morphology is a typical feature of human breast cancer.  The culture of 
breast cancer cell lines in three-dimensional basement membrane recapitulates in 
vivo conditions more closely than conventional monolayer culture and therefore 
morphology can be assessed as a marker for malignancy in vitro.  Associated with 
this aberrant morphology is a deregulation of integrin adhesion receptors. 
In this report, the MCF10a cell line progression series, which consists of 7 cell lines 
that have undergone increasing transformation by H-Ras and xenograft 
transplantations, was studied to assess its suitability for an in vitro breast cancer 
progression model.  The cell lines range from normal MCF10a’s to benign, 
premalignant cells (NeoT, AT1 and DCIS.com) to malignant and metastatic cell lines 
(CA1 variants), all of which are derived from cells of a common genetic origin. 
The different cell lines within MCF10a progression series were grown in a three-
dimensional basement membrane (Matrigel) culture in which they formed complex 
disorganised multi-acinar structures, except the control MCF10a which formed hollow 
acini. Localisation of E-Cadherin, and cell polarity, was also disrupted in malignant 
cell lines.  Analysing β1-integrin expression using flow cytometry, showed similar 
surface expression levels, however confocal microscopy revealed different β1-integrin 
localisation in the malignant cell lines compared to the normal ones.  Treating the 
MCF10a progression panel cell lines with AIIB2, a β1 integrin inhibitory antibody 
resulted in the morphology of the treated 3D colonies becoming more compact, 
smaller, and similar to the MCF10a normal cells.   
In conclusion, this report verifies the MCF10a progression panel as a good model for 
breast cancer progression, especially in a three-dimensional microenvironment and 
independently confirms the possibility for targeting β1 integrin in future breast cancer 
therapies.  
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Introduction 
Disrupted cellular organisation, polarity and cell adhesion are key characteristics of 
breast cancer.  However, how altered cell adhesion is linked to changes in cell 
phenotype is not known.  Detailed mechanistic studies of human cancer have 
primarily been carried out ex-vivo, using established cell lines cultured on two-
dimensional plastic substrata.  Because cells loose many characteristics of their 
differentiated state in monolayer culture, there has been a focus on the developing of 
three dimensional (3D) culture systems for mammary epithelial cells (MECs).  Culture 
within reconstituted basement membrane culture (Matrigel) closely mimics the in 
vivo environment, allowing the study of changes in cellular organisation associated 
with cancer progression (Lee et al., 2007).  The cells recapitulate many features of a 
breast epithelium including formation of hollow acini-like structures with lumen, 
apicobasal polarisation and deposition of a basement membrane (Debnath and 
Brugge, 2005).  MECs cultured in Matrigel are also able to differentiate and produce 
milk under certain conditions (Aggeler et al., 1991; Streuli and Akhtar, 2009).  
Moreover, the organisation and morphology of cell lines cultured in 3D, often 
correlates with their gene expression profiles (Kenny et al., 2007).  
A large number of human breast cancer cell lines have been generated, that originate 
from cells isolated at various stages of breast cancer.  These cell lines can be used 
for investigating specific stages of breast cancer, but are genetically and functionally 
diverse so it is not possible to use them to study the progression of the disease.  In 
order to study the development of cancer in cells with a common genetic 
background, several breast cancer progression cell line models have been developed 
in which the molecular changes could be characterised.  For example, the HMT3522 
S1 normal breast cancer cell line forms hollow spherical acini when cultured in 
Matrigel.  Following spontaneous transformation and selection for EGF-independent 
growth (Briand et al., 1996), the HMT3522 T4-2 malignant cell line was generated 
which has offered various insights into tumour progression (Lee et al., 2007; Weaver 
et al., 1995).  However, the molecular mechanisms that determined malignancy in 
these cells were not defined.  Thus other breast cancer progression models have 
value in dissecting the mechanisms by which malignant cancer arises. 
The commonly used MCF10a cell line is a non-tumourgenic human mammary 
epithelial cell line, derived from normal mammary epithelial cells originating from a 
36-year old patient with fibrocystic disease (Soule et al., 1990).    These cells are 
now immortal, and retain many characteristics of normal mammary epithelial cells.  
When cultured in Matrigel, MCF10a cells develop a similar morphology to MECs in 
normal breast tissue.   This is due to a well described series of events including 
proliferation, cell cycle arrest, polarisation and apoptosis to create a luminal space 
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(Debnath et al., 2003).   The MCF10a normal breast cell line offers a model which 
has been widely used to investigate the ability of certain proteins such ErbB2 and 
TGF-β to induce oncogenic transformation of MECs (Guo et al., 2006; Seton-Rogers 
et al., 2004).   
The MCF10a cell line was used as a starting point for the production of a series of cell 
lines that showed different stages of breast cancer development, known as the 
MCF10 breast cancer progression cell line series (Dawson et al., 1996).  MCF10a cells 
were transformed by transfection with H-Ras to form MCF10AneoT cells and the 
premalignant MCF10AT cell line was subsequently generated after xenograft 
transplantation. Subsequent, trocar transplantation of the MCF10AT cells formed 
carcinomas in 25% of immuno-compromised mice, and selection from these tumours 
generated the MCF10DCIS.com and malignant MCF10CA1 cell lines.  The 
MCF10DCIS.com formed DCIS-like pre-malignant lesions, whereas the MCF10CA1a, h 
and d cell lines produced malignant and metastatic tumours (Miller et al., 2000; 
Santner et al., 2001) (Supp. Fig. 1).  This cell model of breast cancer progression 
therefore provides a range of cell phenotypes observed in non-malignant, 
premalignant and fully malignant and metastatic MECs which are derived from a 
common genetic background. 
Integrins are heterodimeric transmembrane glycoproteins comprising of an α and a β 
subunit that that mediate cell-ECM interactions and transmit environmental 
biochemical cues to inside the cells.  Integrins are critical sensors for the extracellular 
environment that acts to control many cell fates, including cell organisation,  
survival, proliferation and migration and differentiation (Gilcrease, 2007; Streuli, 
2009).  All these processes are disrupted in cancer and may therefore be linked to 
altered integrin expression.  It is now well established that the integrin expression of 
certain subunits are altered in breast cancer and many studies have implicated 
integrins in cancer progression, particularly in growth, apoptosis, invasion and 
metastasis (Rathinam and Alahari, 2010).   
In this report, we describe the morphology of the entire MCF10a progression series 
grown in 3D Matrigel culture, and investigate cell polarity through E-Cadherin 
localisation.  We determine β1-integrin surface expression levels and cellular 
localisation.  We also examine how altering β1 integrin function with the inhibitory 
antibody, AIIB2, affects the morphology and β1-integrin localisation of the cells in 3D 
culture.    
Our results show changes in β1 integrin localisation, but not surface expression may 
affect the cellular morphology of the MCF10a cell lines cultured in 3D and also 
indicates that β1 integrin may be a possible future therapeutic target. 
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Materials and Methods 
Cell culture 
Human breast cancer cell lines in the MCF10a progression series (MCF10a, NeoT, 
AT1, DCIS.com, CA1h, Ca1d, Ca1a) were obtained by Keith Brennan from JR Santner 
(Santner et al., 2001).  The cell lines were cultured in Dulbecco’s Modified Eagle 
Medium Hams F-12 with 15mMs HEPES and L-glutamine (DMEM-F12, Lonza). This 
was supplemented with 5% horse serum (Biosera), 1% penicillin and streptomycin 
(Sigma), 1% L-glutamine (Lonza), 0.5μg/ml hydrocortisone (Sigma), 10μg/ml insulin 
(Sigma), 20ng/ml epidermal growth factor (Sigma) and 100ng/ml cholera toxin 
(Sigma).   
The following established breast cell lines were also used; HB4A, SKBr3, Hs578T, 
Cal51, MDAMB231 and MDAMB468 (all supplied by ATCC) and were cultured in 
Dulbeccos modified Eagle medium (DMEM) (Lonza) supplemented with 10% foetal 
calf serum (FCS), 100 U/ml penicillin, and 100 μg/ml streptomycin (Sigma), 2 mM L-
glutamine (Sigma).   
The AIIB2 hybridoma cell line was purchased from  Developmental Studies 
Hybridoma Bank (Werb et al., 1989).  The cells were cultured in Iscove’s Modified 
Dulbeco’s Medium with L-glutamine and 25mM HEPES (IMDM, Gibco/Invitrogen).   An 
additional 20% Fetal Bovine Serum (Biosera), 10mg/ml gentamicin (Sigma) was 
added and the cell line was cultured in suspension.  The cell line media was collected 
and the rat monoclonal β1-integrin inhibitory antibody was purified from the 
supernatant as described below. 
All cell lines maintained at 37ºC in a 5% CO2 atmosphere. 
Three dimensional cell culture 
The culture plate (6 well plate or 35mm dish) was placed on to a chilled surface and 
coated with Engelbroth-Holm-Swarm (EHS, Matrigel, BD Bioscience) and left to set at 
37°C for 30 minutes. Trypsinised cells from monolayer cultures were counted for 
2.5x104cells in 2ml of media. After 24 hours incubation in a humid atmosphere at 
37°C with 5% CO2, an additional 2% w/v of EHS was added to the media.  The cell 
culture media was changed every 3-4 days.   AIIB2 treated samples initially 
contained 5 μg/ml of purified antibody, this concentration was then increased to 10 
μg/ml whenever media was changed. Cells were maintained in culture for 14 days. 
Immunofluorescence staining 
The MCF10a breast cancer cell lines were cultured in Matrigel on nitric acid treated 
glass coverslips for 14 days.  The cells fixed in 4% paraformaldehyde (made up in 
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PBS) for 20 minutes at room temperature.  Cells were then washed in PBS and 
permeabilised in 0.2% Triton X100 in PBS for 5 minutes at room temperature.  
Samples were incubated with 10% goat serum (Biosera) in PBS for 1 hour at RT.   
Cells were then incubated with primary antibodies β1 integrin (MEM-101A) 
(Invitrogen #CD2900) and E-cadherin (ECCD-2) (BD Transduction) all diluted 1:100 
in 5% goat serum in PBS for 2 hours at room temperature in a humidified chamber.  
The coverslips were then washed in PBS before incubation with a fluorophore 
conjugated secondary antibodies, anti-mouse Alexa fluor 488 (Invitrogen), anti-rat 
Alexa fluor 594 (Invitrogen) or Alexa-594 conjugated phalloidin also diluted in 5% 
goat serum in PBS, for 3 hours at RT in the dark.  After further PBS washes, the 
nuclei were stained with Hoechst 33342 nuclear stain using 4 µg/ml for 2-3 minutes 
at RT.  The coverslips were washed again in PBS before mounting onto twin frosted 
glass slides using ProLong® Gold anti-fade reagent (Invitrogen).  Confocal images 
were acquired by using Leica SP5 inverted confocal microscope prior to processing 
using Adobe Photoshop.  An average of 10 different acini were analysed for each 
condition in each independent experiment.  The experiment was repeated 3 times. 
Flow Cytometry 
Cells were cultured until 95% confluent and washed in cold PBS before harvesting by 
incubating with HBSS/EDTA (HE) (HBSS calcium-free medium containing 4.17 mM 
NaHCO3,  5 mM EDTA and a few drops 0.5% phenol red, preheated to 37oC). Cells 
were gently scraped off the culture dish and transferred to a fresh pre-chilled 
eppendorf tube.   Cells were pelleted by centrifugation at 2000 rpm for 3 minutes at 
4oC and the cells resuspended in 50 μl 1% FCS in PBS. 50μl primary antibody (1 in 
50) was added in 0.02% sodium azide in PBS, mixed and incubated on ice for 1 hour.  
The cells were twice washed in 300 μl 1% FCS in PBS.  The Alexa fluor-488 
secondary antibody was diluted 1 in 200 in 10% FCS in PBS and 50 μl added to each 
sample.  This was then incubated for 45 minutes on ice in the dark.  The cells were 
washed in 300μl 1% FCS in PBS and the pellet resuspended in either 0.5% PFA in 
PBS or PBS.  Flow cytometry analysis was carried out on a DAKO CyAn ADP flow 
cytometer with an excitation wavelength of 488nm laser and the fluorescence is 
measured by a 530/40 bandpass filter.  Data analysis was carried out on Summit 
v4.3 software. Antibodies used for flow cytometry analysis was β1 integrin (K20) 
(Gift from M Humphries). Statistical analysis was carried out by one way ANOVA 
using Prism.  
Western blot analysis 
Protein was extracted from cell lysates using 1x NET buffer (50 mM Tris-Cl, 150 mM 
NaCl, 1% NP-40, and 2 mM EDTA, pH 7.6) for cells on collagen with 1 mM sodium 
orthavanadate, 10 mM sodium fluoride, and 1:100 dilution of Protease cocktail 
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inhibitor set 1 (Calbiochem). Equivalent amounts of protein were determined by 
quantification using a BCA protein assay (Bio-Rad Laboratories) to ensure equal 
loading of proteins. Cell lysates were subjected to SDS-PAGE then transferred to 
nitrocellulose membranes which were blocked in 5% milk and then incubated 
overnight at 4oC with specific antibodies.  The membranes were incubated with the 
HRP-conjugated secondary antibodies (Jackson laboratories) and signals detected by 
enhanced chemiluminescence reagent (ECL: Pierce) or Odyssey detection system (Li-
Cor).   Antibodies used included β1 integrin (8E3), α3 (P1B5) (both gifts from M 
Humphries), β4 integrin (Santa Cruz #sc-9090), Calnexin (Bioquote #SPC-108A/B). 
Purification of the β1 integrin inhibitory antibody, AIIB2 
Isolation of the AIIB2 antibody from culture medium of the hybridoma cell line was 
achieved using Montage Antibody Purification Kit and Spin columns with PROSEP-G 
Media (Millipore). Firstly, the culture supernatant was filtered (50mls per column) 
using a 0.22 Steriflip-GP device (Millex) then diluted 1:1 v/v with binding buffer (1.5 
M glycine (Fisher Scientific), 3 M NaCl (Melford), pH 9.0). This sample was added to 
pre-equilibrated spin columns and centrifuged using the MULTIFUGE 3 S-R HERAEUS 
centrifugal machine for 20 minutes at 150 x g. After removal of unbound 
contaminants, the spin columns were washed twice using 10ml of binding buffer and 
centrifugation for 2 minutes at 500 x g. Columns were then transferred to fresh 
centrifuge tubes containing 1.3ml neutralisation buffer (1M Tris (Biorad), pH 9.0) and 
the bound IgG was eluted through centrifugation for 5 minutes at 500 x g with 10 ml 
of elution buffer (0.2 M glycine, pH 2.5). The final desalting and concentrating of the 
remaining antibody solution was obtained through addition of the sample to the 
Amicon Ultra-15 centrifugal filter device with 30, 000 NMWL (Millipore) and 
centrifugation for 30 minutes at 4000 x g. AIIB2 concentration was subsequently 
measured using the Spectrophotometer ND -1000 Nanodrop.  The antibody was 
sterilised through 0.2 μm filter before use and stored at -20°C. 
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Results 
Malignant cell lines form multi-acinar cellular masses in three dimensional 
culture 
All seven cell lines from the MCF10a breast cancer progression panel were cultured in 
reconstituted basement membrane (Matrigel) or Matrigel to assess the morphology 
and behaviour of the cells in this 3D environment.  Cellular morphology was observed 
using phase contrast microscopy. 
After 7 days of culture, MCF10a cells formed spherical acini structure, although the 
lumens were still full of cells.  NeoT and AT1 cell structures also had an acinar-like 
appearance as they were spherical in shape, but they were larger in size compared to 
the MCF10a and occasionally much larger irregular structures could be seen (Figure 
1).  DCIS.com cells did not form smooth spherical structures at day 7; instead they 
resembled disorganised masses of cells that sometimes formed a circular shape.    
The CA1 variants showed irregular spherical structures that appeared to have cells 
protruding from the main structure, possibly migrating and invading through the 
matrix.  This was particularly noticeable in CA1h and CA1d cell lines (Figure 1). 
After a further 7 days of culture, at day 14, the MCF10a cells formed spherical acini, 
with a smooth outer edge and a hollow lumen.  The NeoT and AT1 acinar-like formed 
large irregular, disorganised structures of varying sizes and some of the larger 
structures appeared to have joined up (Figure 1).  In contrast, DCIS.com structures 
had an irregular shape and cells were seen outside the large cellular mass.  Cells 
could be observed in the Matrigel surrounding large cellular structures in CA1h and 
CA1d cells were able to form long branched tubular like structures that join up to 
form a network of interconnected cell masses.  These structures did not have an 
organised morphology.  CA1a form large disorganised multi-cellular structures, 
although they did not have cell outside the main large structure unlike the other CA1 
variants (Figure 1). 
In summary, the more malignant cells (CA1 variants) grown in 3D culture develop 
into disorganised cell masses that do not resemble acini.  They form tube-like or 
large round structures with cells protruding into the surrounding ECM.  This is in 
contrast with the pre-malignant NeoT and AT1 cells, which had a disorganised 
morphology, but the cells are maintained within the acinar structure (Figure 1). 
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Heterogeneous cell-cell junction formation in malignant cells of MCF10a 
progression series 
Since loss of polarity and cellular organisation are key characteristics of malignancy, 
we assessed the localisation of E-Cadherin and actin in MCF10a breast cancer 
progression panel using immunofluorescent staining and confocal microscopy. 
Staining for E-Cadherin in the MCF10a progression series revealed a different 
localisation between the non malignant and malignant cell lines (Figure 2).  In 
general, E-Cadherin is at the cell-cell boundaries in MCF10a, NeoT and AT1, 
especially in the outer layer of cells, however this was not always easily identifiable in 
the images.  In contrast, DCIS.com, CA1h, and CA1h show heterogeneous E-
Cadherin localisation.  The cell-cell junctions have some E-Cadherin, but the levels 
are much lower than the non-malignant cell lines and unlike the other cell lines, it 
can be seen on multiple cell surfaces, not just the basal layer (Figure 2).  Overall, the 
localisation of E-Cadherin is disorganised in the malignant cell lines compared to the 
non malignant cell lines.   
In addition, the f-actin staining showed mostly apical localisation in MCF10a (not best 
image provided in Figure 2), whereas in NeoT and AT1 the actin staining was 
localised to the centre of the cellular mass.   In the malignant cell lines, the actin 
staining was weaker and showed an irregular localisation, thus indicating that there is 
a complete loss of polarity in the malignant cell lines (Figure 2). 
In summary, the control normal MCF10a cell line that show cell polarity, with E-
Cadherin localised on the cell-cell junctions and actin on the apical surface (this was 
observed generally in the cultures, though the image provided in Figure 2 does not 
represent this as well as it could).  The non-malignant cell lines NeoT and AT1 show 
some aspects of cellular polarity as E-Cadherin is correctly localised around the outer 
layer of cells, despite there being a filled lumen, but the actin staining is 
disorganised. In contrast, the malignant cell lines show disorganised E-Cadherin and 
actin localisation suggesting a complete loss of cell and tissue polarity. 
The distribution of β1 integrin, but not surface expression levels is altered in 
malignant cell lines. 
Changes in the expression of integrins have been associated with the progression of 
cancer cells to malignancy (Guo and Giancotti, 2004).  β1 integrin has a central role 
in regulating the function and development of the mammary gland and is required for 
the formation of polarised acini (Naylor et al., 2005).  We examined if there was a 
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link between the surface β1-integrin levels and the characteristics of malignancy of 
the MCF10a series.  Flow cytometry was used to measure surface integrin levels. 
The surface levels of β1 integrin did not change significantly in any of the cell lines of 
the MCF10a progression panel and the CA1 variants (Figure 3). It was statistically 
analysed using a one way - ANOVA with no significance detected.  A similar result 
was seen by analysis of β1 integrin by western blotting on a panel of breast cancer 
cell lines (Supplementary Figure 2).  β1-integrin levels were generally similar across 
the panel of cell lines which included normal, non-malignant and malignant cell lines.  
The different bands on the western blot represent the various glycosylated forms of 
β1 integrin (Bellis, 2004). 
Since there were no significant alterations in β1 integrin surface levels in the MCF10a 
series, we used immunofluoresence and confocal microscopy to determine if the 
localisation of β1 integrin changed.  The staining revealed that β1 integrin was 
distributed at the basal cell surface on MCF10a, NeoT, AT1 and DCIS.com cell lines, 
and formed a complete ring around the outer edges of the structure (Figure 4).  In 
DCIS.com, although the β1 integrin was localised to the basal surface, it did not form 
a complete ring around the structure and cells can be seen outside of the cellular 
mass.  CA1h and CA1d have disorganised β1 integrin staining and which is dispersed 
throughout the cells and not just located at the outer cell surface (Figure 4). 
In the malignant CA1 variants, β1 integrin was distributed over the entire structure in 
a disorganised manner, whereas the normal or pre-malignant cell lines β1 integrin 
was only at the basal surface, but the overall levels are similar. These data 
demonstrate that increased malignancy can result in changes in the organisation and 
distribution of cell adhesion molecules within multi-cellular aggregates, even though 
the levels of surface expressed protein remain similar.   
Reversion of cellular morphology and re-localisation of β1 integrin in the 
malignant cell lines by inhibition of β1 integrin with AIIB2  
β1 integrin has an important role in breast cancer progression, particularly in growth, 
invasion and metastasis (Korah et al., 2004; Lee et al., 2005; Pontier and Muller, 
2009; White et al., 2004).  By down-modulating β1 integrin activity using a rat 
monoclonal β1-integrin inhibitory antibody, AIIB2 (Werb et al., 1989), some breast 
cancer cells showed a reversion phenotype in cellular morphology (Park et al., 2006; 
Wang et al., 2002; Weaver et al., 1997).  To determine whether the altered β1 
integrin location within the MCF10a progression series was causative for altered 
acinar structure, we treated the cells with a function blocking antibody, AIIB2, during 
the course of culture.  
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The MCF10a cell lines were cultured in Matrigel for 14 days with and without 10 
μg/ml AIIB2.  Previous studies indicated that localisation of integrins to basolateral 
surface is integral to the structural organisation of non-malignant mammary cell 
colonies (Weaver et al., 1998) therefore we examined the localisation of β1 integrin 
as a marker for cell polarity in the control and AIIB2 treated cells by confocal 
microscopy after 14 days of culture (Figure 5).    
Treatment with AIIB2 of the MCF10a and NeoT cell lines resulted in smaller cell 
clusters with filled interiors (Figure 5). However, the large disorganised structures of 
the malignant MCF10a CA1 cell lines became smaller, more compact and spherical in 
shape upon inhibition of β1 integrin.   
Confocal microscopy revealed the localisation of β1 integrin in MCF10a and NeoT was 
depolarised after AIIB2 treatment, with β1 integrin being observed inside the cell 
clusters rather than purely at the basal surface (Figure 5). However, in the CA1 
variants treated with AIIB2, β1 integrin is localised at the basal surfaces, in contrast 
to controls that are distributed throughout the entire structure.  This re-localisation of 
β1 is particularly notable in the CA1h and CA1d variants.   These results suggest that 
inhibition of β1 integrin signalling may cause the redistribution of β1-integrin and 
polarity may be re-established.  
In conclusion, we show that β1-integrin surface level does not change, however the 
β1-integrin localisation and distribution is much more disorganised in the malignant 
cell lines.  In addition, we show that inhibition of β1 integrin partially restores cellular 
polarity in malignant cell lines, with β1-integrin being redistributed to the basal 
surface after treatment. 
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Discussion 
The isogenic MCF10a progression series is a potentially powerful system for studying 
mammary tumourigenesis.  The cell lines are derived from a common ancestor and 
therefore have similar genetic background and the manipulations that have 
progressively transformed the cell lines are well defined (Santner et al., 2001).  The 
power of three dimensional cell culture models has become more apparent in recent 
years, with the wider use of matrices such as laminin-rich basement membrane 
substitutes or Matrigel being used, especially in culture of mammary epithelial cells 
(Debnath and Brugge, 2005).   However, many studies are still carried out in 
conventional 2D culture rather than 3D culture, although there are numerous reasons 
why 3D culture is advantageous, especially when investigating cancer.  For example, 
tissues in vivo are maintained in 3D not 2D, and true multi-cellular interactions are 
unable to be studied in 2D.  2D culture places tension on cells that they are not 
exposed to in vivo and this leads to changes in cell function (Butcher et al., 2009). 
Breast cancer oncogenes also have different effects in 2D and 3D; for example, over-
expression of ErbB2 in MCF10a has no effect in 2D culture, but profound effects in 3D 
(Muthuswamy et al., 2001).   In addition, there are very few studies of cancer cells in 
3D, with existing studies being restricted to the normal HMT3522 S1 and T4-2 
malignant cell line and the transformation of normal breast epithelia such as the 
MCF10a and primary MECs (Briand et al., 1996; Lee et al., 2007; Seton-Rogers et 
al., 2004). 
In this study, we assessed the morphology of the MCF10a progression series cultured 
in 3D and showed that the malignant cell lines of the MCF10a series formed complex 
disorganised multi-acinar structures, with more cells in the surrounding matrix which 
may suggest cellular invasion.  Our results are supported by an earlier study which 
carried out basic morphological characterisation of a few of cell lines of the MCF10a 
progression series (MCF10a, MCF10AT1 and CA1a only) in 3D Matrigel culture 
(Imbalzano et al., 2009).   They described the MCF10a series as a good breast cancer 
progression model, with certain characteristics such as continuation of proliferation 
and the loss of polarity mimicking similar stages in breast cancer. However, they did 
not examine molecular markers of cell adhesion or carry out functional studies to 
identify a role for integrins in breast cancer progression.  The morphology of the 
malignant MCF10a CA1 cell lines can be described as grape-like, which may correlate 
with gene expression such as  lower levels of E-cadherin and β-catenin (Kenny et al., 
2007). We assessed the localisation of the polarity markers such as the cell-cell 
adhesion receptor, E-Cadherin, and actin.  Both were disrupted in malignant MCF10a 
cell lines, compared to the normal and benign cell lines, further showing that 
malignancy leads to a loss of tissue and cellular polarity. 
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Loss or redistribution of the cell-cell adhesion receptor, E-Cadherin, is an important 
occurrence in epithelial to mesenchymal transition (EMT).  EMT is a key step in 
cancer progression (Blick et al., 2008).  The loss or decrease in E-Cadherin, often by 
the transcriptional repression by the transcription factors Snail, Slug and Twist 
(Barrallo-Gimeno and Nieto, 2005; Bolos et al., 2003; Yang et al., 2004) in addition 
to TGF-β signalling (Zavadil and Bottinger, 2005), leads to a more migratory 
phenotype, with the cells having fewer epithelial and more mesenchymal 
characteristics.  This transcriptional down-regulation of E-Cadherin is due to 
promoter methylation in cancer cells (Lombaerts et al., 2006).   Although, we did not 
study the migration of these cells, the loss of E-cadherin and the increase in the cells 
seen outside of the main cellular structure may suggest that the CA1 variants have 
undergone EMT and have acquired an invasive phenotype.  It would be interesting to 
determine the migratory ability of the MCF10a panel in future, as well as identifying 
other markers for EMT such as vimentin, Snail and Slug (Zhou et al., 2004), 
especially as slug has been shown to be able to regulate integrins in other cells types 
(Turner et al., 2006).  
Studies in our lab have shown that changes in β1 integrin leads to changes in 3D 
organisation in breast epithelia (Naylor et al., 2005).  In this study we investigated 
whether changes in β1 integrin could explain the changes in cellular morphology 
observed in breast cancer tumourigenesis using the MCF10a breast cancer 
progression model.  We show that there are no significant changes in β1 integrin 
levels on the cell surface throughout the cell lines, but our results suggest there are 
changes the organisation of β1 integrin in the cell lines when cultured in 3D and 
therefore conclude that changes in the distribution of β1 integrin may explain the 
changes in 3D morphology. However more data is required to show this more 
convincingly. 
Loss of tissue polarity, particularly at the basolateral surfaces is one of the 
characteristic alterations of the breast tumour phenotype. In the malignant cell lines 
of the MCF10a progression series, the diffuse or incorrect localisation of both E-
Cadherin and β1 integrin in 3D Matrigel culture corroborates the usefulness of this 
breast cancer progression model.  In particular, it suggests that the point in cancer 
progression which these changes take place is the conversion to malignancy. 
Previous studies have shown that treatment of breast cancer cell lines with the β1 
inhibitory antibody, AIIB2, in 3D culture leads to changes in morphology, with the 
cells becoming more organised, polarity being restored and increase in apoptosis 
reforming the hollow acini and reverting the cell lines to a more normal phenotype 
(Park et al., 2006; Weaver et al., 1997).  Here we find that treatment with AIIB2 in 
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the MCF10a progression series, changes the morphology of the cancer lines 
becoming more compact with less invasive cells.  β1 integrin redistributes to the 
basal surface of the acini, however it does not revert to a normal phenotype as 
apoptosis does not take place and the acini remain full of cells. 
Inhibiting β1 integrin using AIIB2 in the breast cancer cell lines including HMT-3522 
T4-2, MCF7 and Hs578T was originally shown to lead to a reversion in the 
morphology of the cell cultured in 3D to form phenotypically normal structures 
(Weaver et al., 1997) (Wang et al., 1998).  AIIB2 treatment lead to loss of cancer 
cells, due to a reduction in  cell proliferation and an increase in apoptosis (Park et al., 
2006).  Furthermore, the magnitude of reversion phenotype of different breast 
cancer cell lines in 3D culture depended on malignancy of the cells and the 
combination and number of the β1 integrin, EGF, PI3K and MAPK inhibitors (Wang et 
al., 2002).  However these studies using AIIB2 have not been carried out on a 
progression model before and especially not the MCF10a panel, so this report 
extends on these reports.  Immunofluorescent staining of the MCF10 panel indicated 
redistribution of adhesive protein β1-integrin upon incubation with AIIB2.  
Demonstration of this relocalisation is consistent with previous findings of β1-
mediated distribution of E-Cadherin, β4 and α6 integrins (Weaver et al., 1997). 
β1 integrin heterodimers have been widely implicated in various stages of breast 
tumourigenesis over the years with data from both in vivo and in vitro studies 
showing the importance of this subunit in breast cancer progression  (Gui et al., 
1995; Mechtersheimer et al., 1993; Shaw, 1999; Wewer et al., 1997).   
In general, it appears that a loss in expression of β1 integrin heterodimers is 
associated with larger tumours (Jonjic et al., 1993) and increased invasiveness (Gui 
et al., 1995).  However, it is currently unclear whether this relates to patient survival 
as some studies have shown a decrease in β1 integrin expression having no 
correlation (Berry et al., 2004), a poorer (Gonzalez et al., 1999) or a better outcome 
(Yao et al., 2007). However, despite these contrasting studies, changes in β1 integrin 
are not picked up as changes in gene expression in microarrays (Allinen et al., 2004; 
Rhodes et al., 2004; West et al., 2001) 
The data presented in this report, shows that other mechanisms could be important 
because there are no changes in expression throughout in the MCF10a panel, but 
there are changes in localisation.  Moreover, AIIB2 can alter 3D cellular properties 
since it prevents invasive characteristics and induces more compact colonies.  But it 
does not revert the cells to normal MCF10a morphology with hollow acini. Even 
though there may not be changes in integrins at the RNA level (as suggested by 
numerous microarrays) (Rhee et al., 2008; Rhodes et al., 2004; Sorlie et al., 2001)or 
surface expression as shown in this report, the changes in β1 integrin distribution 
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may be of fundamental importance and lead to changes in migratory or other cell 
characteristics that are associated with increased malignancy.   
Overall, there are limitations to cell line models, even in 3D culture as cancer is a 
disease that includes many genetic changes and in addition to an altered 
microenvironment, that is very difficult to recapitulate in a culture dish.  However, 
using model systems such as the MCF10a breast cancer cell line progression series 
can give insights into breast tissue morphogenesis and tumourigenesis.  The MCF10a 
series in one of the better model systems to use due to its common genetic 
background and known transformation events and can be useful in the future to 
investigate and gain a better understanding of breast cancer.   
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Figure Legends 
Figure 1: Phase contrast microscopy of MCF10a breast cancer progression 
series cell lines grown in Matrigel.  Cell lines from the MCF10a breast cancer 
progression panel (MCF10a, NeoT, AT1, DCIS.com, CA1h, Ca1d, CA1a) were grown in 
3D Matrigel.  Phase microscopy images were captured when at day 7 and day 14 of 
culture at x10 and x20 objective to determine cellular morphology in 3D culture 
conditions. The arrows are indicating the key points as mentioned in the results 
section. 
 
Figure 2: Immunofluoresence analysis of E-Cadherin and Actin in MCF10a 
progression panel cultured in Matrigel.  Cell lines from MCF10a progression panel 
were cultured for 14 days in 3D Matrigel and stained with (i) E-Cadherin (green) and 
actin (TRITC –phalloidin)(red) to examine cell-cell junctions. The staining was 
analysed using single confocal sections and the nuclei were stained with DAPI. 
 
Figure 3: β1 Integrin expression analysis of MCF10a breast cancer 
progression cell line panel by flow cytometry.  Cell lines from the MCF10a 
progression panel were stained with anti-β1 integrin antibodies and analysed by flow 
cytometry.  (i) Histograms of a representative data set of β1 integrin analysis for 
each cell line, with negative control in black and β1 integrin in green. (ii) The relative 
mean florescence intensity of β1 integrin expression of the MCF10a, NeoT, AT1, 
DCIS.com, CA1h, CA1d, CA1a cell lines.  Data are presented as averages ± SEM, 
from 5 independent experiments.  Statistical analysis was carried out using Prism and 
no significant changes were identified. 
 
Figure 4: Immunofluoresence analysis of β1-integrin in MCF10a progression 
panel cultured in Matrigel.  Cell lines from MCF10a progression panel were 
cultured for 14 days in 3D Matrigel and stained with β1 integrin (green) and actin 
(red) to determine the morphology and polarity of cell-ECM adhesions.  The staining 
was analysed using single confocal sections and the nuclei were stained with DAPI. 
 
Figure 5: Morphology and β1 integrin localisation in MCF10a progression series in the 
presence and absence of β1 inhibitory antibody, AIIB2 cultured in Matrigel.  Cells 
were plated onto Matrigel and incubated with or without AIIB2 antibody (10μg/ml). 
132 
 
Immunofluoresence staining and confocal microscopy were used to analyse 
expression and localisation of β1 integrin. Scale bar: 5µm. 
 
Supplementary Figure 1: Derivation of MCF10a breast cancer progression 
cell line series.  MCF10A cells were originally isolated from benign breast tissue 
from a patient with fibrocystic disease.  The cells then underwent transformation by 
H-Ras transfection to form the MCF10neoT cell line. Xenograft passages of 
MCF10NeoT produced MCF10AT1 cells and subsequent trocar transplantation formed 
the MCF10DCIS.com which formed DCIS like lesions when transplanted and the 
MCF10CA1 variants (CA1d, CA1h, CA1a) that formed malignant and metastatic 
tumours after transplantation. 
 
Supplementary Figure 2: Integrin expression levels in breast cancer cell 
lines.  A panel of breast cell lines were grown in culture and harvested when 
approximately 95% confluent.  60μg protein of each lysate was separated by SDS-
PAGE and expression of the β integrin subunits and α3 integrin was analysed by 
immunoblotting. Each blot was repeated three times and a representative is shown.  
The receptor status of each cell line for Estrogen Receptor (ER), ErbB2 and Epidermal 
Growth Factor Receptor (EGFR) is indicated that was determined by Fiona Foster.  
Calnexin was used as a loading control and the molecular weights (kDa) are shown 
on the left hand side. 
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In this thesis, I have described the development of a new methodology to study the 
proliferation of primary MECs over a longer period of time (Chapter 2).  MECs show a 
burst of proliferation during the first 48 hours of culture that subsequently drops off 
to an almost undetectable level. We find that by culturing MECs in 3D for up to 7 
days, before isolation using EDTA/PBS and replating to 2D, allows the proliferation to 
be analysed over the longer term.  This method enables experiments that involve 
determining the effect of proliferation after manipulation, such as gene transfer 
through viral infections, can be carried out.  Using this method, the 
infections/transfections can be performed after directly after extraction from the 
mammary gland and the cells cultured in Matrigel whilst gene 
deletion/expression/turnover occurs (Akhtar et al., 2009).  The altered acini can then 
be isolated and the proliferation analysed.    
This new methodology is then utilised when dissecting the signalling mechanisms by 
which β1 integrin controls proliferation in primary MECs (Chapter 3).  By removing β1 
integrin genetically in situ, I have presented evidence that β1 integrin provides 
unique signals that are required for the regulation of epithelial cell cycle.  Previous 
studies have shown that β1 integrins are necessary for proliferation in the mammary 
gland (Faraldo et al., 2001; Klinowska et al., 1999; Li et al., 2005), but the exact 
mechanism by which integrins regulate proliferation in MECs was unclear.  In this 
thesis, I show that the mechanism is through a decrease in Rac activity and ERK 
translocation to the nucleus, but does not involve ERK phosphorylation. Although 
Rac1 activity and ERK localisation has been shown to be affected in other cell types, 
e.g. fibroblasts, this has not been shown before in MECs (Aplin et al., 2002; Hirsch et 
al., 2002).    
β3 integrin is up-regulated in the absence of β1 integrin and assembles the basic 
core components of focal adhesions, but there must be something specific about β1 
complexes that enables it to signal regulate proliferation.  Integrin adhesions must 
therefore be cell-fate specific as both β1 and β3 adhesions both support migration, 
but only β1 integrin mediates proliferation.  We therefore show for the first time that 
regulation of cell fate by integrins in epithelial cells may be dependent on the 
presence of specific integrin subunits that activate particular signalling pathways.  
The different mechanisms by which different integrins signal are of great interest, in 
particular the involvement of unique sets of adapter proteins that bind to different 
integrin tails confer the different integrin functionality  (Legate and Fassler, 2009).  
This study contributes to this field by showing that different integrin subunits function 
by activating different signalling pathways leading to various cell fates such as 
proliferation and migration.  Although the differentiating adapter protein in this 
system is unknown at this moment, it will be exciting to decipher this in the future.   
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By investigating how integrins regulate proliferation in normal MECs can lead to new 
discoveries in the mechanisms behind breast cancer tumourgenesis. Studying 
integrins in breast cancer progression cell line models can start to reveal insights into 
this that may potentially result in some novel therapies.  I have characterised a 
recently generated breast cancer progression cell line model, the MCF10a series 
(Santner et al., 2001), in three dimensional Matrigel culture and assessed the 
expression and localisation of β1-integrin in the different cell lines to determine its 
suitability as a breast cancer progression model (Chapter 4).  This study extends on 
the recently published work by Imbalzano et al, and describes the entire series and 
shows that the morphology in Matrigel reflects the corresponding stage of breast 
cancer, with increasing loss of polarity as you progress through the series to 
malignant cell lines (Imbalzano et al., 2009).  Further to this, treatment with the β1 
inhibitory antibody, AIIB2, changes the morphology of the malignant CA1 variants in 
3D to a more compact structure, and β1 integrin is relocalised to the basal surface.  
A similar effect was seen by AIIB2 on other breast cancer cells lines, although the 
effect of AIIB2 has not been studied in a progression model and it opens up the 
possibility of the inhibition of β1 integrin being a possible avenue for breast cancer 
therapy (Park et al., 2006).  Overall, the MCF10a progression series is a potentially 
powerful system for studying mammary tumourigenesis and this study shows that it 
could be useful to investigate many aspects of breast cancer progression, but as 
always the limitations of cell line model must be considered. 
Future Directions 
The work in this thesis raises many questions that it would be interesting to further 
investigate in the future.  For example, what are the changes in signalling and 
mechanisms behind the proliferation block of primary MECs in 2D culture?  Why is 3D 
culture permissive for maintaining the window for cell division but 2D culture not?  
Could it be down to changes in expression of specific receptors such as estrogen 
receptor, and signalling pathways in the different environments or dependent on cell 
shape and cellular tension that permits proliferation.    It would also be necessary to 
determine why the cells permanently exit cell cycle when cultured in 2D?  Do they 
enter senescence or another state whereby the cells do not proliferate? 
I also present some interesting developments in the mechanisms by which integrins 
regulate proliferation in MECs, but it raises many further questions that must be 
addressed in the future.  It raises the question of whether control by integrins on cell 
fate is dependent on specific integrin subunits such as β1 integrin and that despite 
the similarity of β1 and β3 adhesion complexes there must be differences in 
signalling because of the cell cycle phenotype. For example may differences in a 
specific GEF, which would explain the difference in Rac activation.  A proteomics 
approach isolating the different adhesome components would be a suitable technique 
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to use to identify the unique proteins in both β1 and β3 adhesions complexes and 
reveal the key signalling differences and molecular links (Humphries et al., 2009). 
Another possibility for the decrease in Rac activity in the β1 null, β3 positive cells 
could be that active Rac in β1 control MECs may cause β3 integrin mRNA turnover.  
This explanation will have to be further investigated. In addition, a rescue experiment 
to determine whether Rac can rescue proliferation in β1 null MECs would provide 
support my proposed mechanism.  To further investigate the mechanisms, it would 
be interesting to carry out a rescue experiment using β1 integrin, β3 integrin or a 
β1/β3 chimera protein to see which one could rescue proliferation.   
The difference in ERK nuclear localisation between control and β1 null β3 positive 
MECs raises the questions about how exactly is ERK translocated to the nucleus and 
mechanism that links integrins, Rac and ERK nuclear translocation.  It would also be 
important to determine whether them same mechanism occurs in 3D culture. 
The evidence presented in this thesis raises some interesting questions about the 
control of proliferation by integrins in breast cancer.  If integrin expression 
significantly changes during tumourigenesis, with increase in β3 integrin and loss of 
other subunits, then additional oncogenic changes must be present to enable the 
MECs to undergo uncontrolled proliferation in the presence of integrin changes that 
may in fact block proliferation.  Focal adhesions signalling proteins such as FAK, have 
been shown to be significantly up-regulated in breast cancer and is involved in an 
aggressive phenotype (Lark et al., 2005).  Could overactive focal adhesion signalling, 
along with other well known oncogenes such as ErbB2 and Notch overcome normal 
proliferation controls by integrins and lead to the deregulated proliferation seen in 
breast cancer?  The β1Itgfx/fx;CreER™ MEC cell culture system would provide an ideal 
opportunity to begin to answer this question, by performing rescue experiments with 
constitutively active FAK and Notch as well as other oncogenes such as ErbB2 and c-
myc on the β1 null MECs.   
In conclusion, in this thesis I show the critical role that β1 integrins have in 
regulating proliferation in MECs and the mechanism by which they exert this control 
is through Rac and ERK nuclear localisation. This finding could potentially be used in 
determining new therapies for breast cancer. 
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Supplementary Methods 
1.0 Mouse Strains and Breeding 
1.1 Generation of β1integrinfx/fx;Cre-ER mouse strain 
Itgβ1fx/fx;Blg-Cre mice were crossed with Cre-ERTAM+/- mice to generate the mouse 
line Itgβ1fx/fx; Cre-ERTAM+/-. Offspring carrying both transgenes were identified by 
genotyping using polymerase chain reaction (PCR) as described below and breeding 
pairs set up using mice with the desired genotype (Figure A1).  
1.2 Genotyping of Transgenic Mice 
DNA was extracted from ear punches and the genotype analysed by PCR for the β1 
integrinfx/fx allele and the presence of the Cre-ER transgene (CreER+/+ or CreER-/+ 
genotype).  The ear punches were digested in lysis buffer (50 nM Tris, 0.1 M NaCl, 5 
mM EDTA and 0.5% SDS) with 100 μg/ml proteinase K, overnight at 55oC.  The 
genomic DNA was isolated using isopropanol precipitation and the DNA resuspended 
in PCR grade water.   
For detection of the β1 integrinfx/fx allele by PCR, the following primers and conditions 
were used: Forward primer: 5’-GCCGCCACAGCTTTCTGCTGTAGG-3’, reverse primer: 
5’-CTGATCATTCCAATCCAGGAAACC-3’, 94 oC for 5 min, 35 cycles of (94 oC for 1 min, 
64 oC for 1 min, 72 oC for 1:30 min) and a final elongation step of 72 oC for 10 min 
resulting in a products of 335 bp (β1integrinfx/fx allele) and 300 bp (wildtype β1 
integrin allele) (Figure A2a).   
For detection of expression of Cre-ER, the following primers and condition were used: 
Forward primer 5’-AACCTGGATAGTGAAACAGGGGC-3’, reverse primer 5’-
GGAACCGACTTGACGTAGCCAGC-3’, 94 oC for 5 min, 30 cycles of (94 oC for 30 secs, 
56 oC for 30 secs, 72 oC for 1 min), and an elongation step of 72 oC for 7 mins 
resulting in the amplification of a 540 bp product (Figure A2a). 
The PCR products were visualised by resolving on a 1 or 2% agarose gel, depending 
on the expected product, using 200 ng/ml ethidium bromide. The agarose gels were 
electrophoresed at 100V and DNA fragments visualised by UV transilluminator.  
2.0 Primary Mouse Mammary Epithelial Cell Culture 
2.1 Preparation of Collagen and other ECM protein coated cell culture dishes  
Rat tail collagen I was diluted in cold PBS to give a final concentration of 10 μg/ml 
and dishes were coated with 100 ul per cm2 dish area, resulting in a coating density 
of 10 μg/cm2. Plates were also coated with other ECM proteins at the following 
concentrations; laminin (12 μg/ml) fibronectin (12 μg/ml) and vitronectin (3 μg/ml) 
(All from Sigma).  The ECM protein/PBS mixture was incubated overnight at 4oC or 1- 
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Figure A1: Generation and Genotyping of Itgβ1fx/fx; Cre-ERTAM+/- mouse lines 
A) β1 fx/fx +/+  and CreER+/- were crossed together generating mice with genotypes 
β1 fx/fx +/- :CreER -/- , β1 fx/fx +/- :CreER +/-  and β1 fx/fx +/- :CreER +/-.  β1 fx/fx +/- 
:CreER +/-  and β1 fx/fx +/- :CreER +/- were paired generating offspring with the nine 
genotypes illustrated.  The desired genotypes (β1 fx/fx +/+ :CreER +/+ and β1 fx/fx +/+ 
:CreER +/-) for which the cells could be used in experiments are highlighted in a red 
box. 
B) The mice were genotyped using PCR of genomic DNA.  The β1Itgfx/fx allele was 
detected by a band at approximately 350bp, whereas the wildtype band was around 
300bp.  Lane 1 shows a homozygous mouse, whereas lane 2 shows a heterozygous 
mouse.  The CreER allele was detected by the presence of a band at 540bp.  Lanes 1 
and 2 shows the presence of this transgene so these mice could be homozygous or 
heterozygous individuals, whereas lanes 3 and 4 are wildtype with no detection of the 
CreER transgene. 
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2 hours at 37oC.  After coating the dishes were washed with cold PBS before 
conditioning with the serum/fetuin mix (20% FCS, 1 mg/ml fetuin in Hams F12 
medium 0.45 μm sterile filtered.  Supplemented with 100 μg/ml gentamycin, 200 
U/ml penicillin, 200 μg/ml streptomycin, 0.5 mg/ml fungizone, 20ng/ml EGF, 10 
μg/ml insulin,  2 μg/ml hydrocortisone), for approximately 3-4 hours at 37oC before 
plating the cells. 
The serum glycoprotein Fetuin is found in serum that is used to supplement growth 
media during cell culture.  The precise role of fetuin has remained a mystery for 
many years, but it has been commonly used an enhancer of cellular attachment to 
promote the adhesion of cells to the culture dish after isolation (Nie, 1992).  In a 
recent study, Fetuin has been purified and identified to have a critical role in growth 
signalling in breast cancer cells though PI3Kinase and Akt. The interaction of the cells 
and fetuin was Ca2+ dependent  (Sakwe et al., 2010) 
2.2 Isolation of Primary Mouse Mammary Epithelial Cells 
The five pairs of mammary glands were isolated from 14.5 to18.5 day pregnant ICR 
or β1integrinfx/fx;CreER mice.  The mice were sacrificed by CO2 overdose and the 
mammary gland removed.  Extracted tissue was put into tubes containing Hams F12 
medium and chopped on a Teflon board for 15 minutes using four scalpels held 
together. The finely chopped tissue was digested in 70ml collagenase mix (14 mM 
NaHCO3 , 10 mM HEPES, 9.8 mg/ml nutrient mixture Hams F10, 1.5 mg/ml porcine 
trypsin, 3 mg/ml collagenase, 5% FBS, all sterile filtered) for 1 hour 15 minutes at 
37oC with agitation. 
The digested tissue was centrifuged at 16g for 1 minute; the supernatant was 
transferred to a new tube, whereas the remaining pellet containing any undigested 
tissues was redigested with 30ml of fresh collagenase mix for 30 minutes.  The 
supernatant was centrifuged at 110g for 3 minutes, and the pellet was resuspended 
in 15ml Hams F12 medium and kept on ice (pellet #1). The supernatant was 
centrifuged at 375g for 10 minutes to give pellet #1a, which was kept on ice. 
The redigested tissue was centrifuged (110g for 3 min) to give pellet #2 and the 
resulting supernatant (375g for 10 minutes) to produce pellet #2a.  Pellet #1a and 
#2a were combined and further centrifuged at 110g for 3 min.  The final 
centrifugation step at 110g leaves a supernatant containing mainly fibroblasts and 
haemopoetic cells whereas the pellet is highly enriched in epithelial cells.  All three 
pellets were combined and divided into two tubes for the final washing steps. The 
pellets were resuspended in 45ml Hams F12 medium and centrifuged at 110g for 3 
min.  This step was repeated twice more, washing the cells.  The cells were also 
collected from the supernatant of each by centrifugation at 110g for 3 min.  The final 
cell pellets were combined, resuspended in Hams F12 medium to a final volume of 
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50ml and plated onto plates coated with the required ECM protein, conditioned with 
serum/fetuin.  Cells were plated such that the volume equivalent to one mouse was 
plated on 3 x 145mm collagen dish or 1 x 145mm Matrigel dish. This resulted in an 
approximate cell density of 2.5-5 x 105 cells per cm2.  If smaller amounts of tissue 
were collected, the volume equivalent to one mouse was adjusted to 2 x 145mm 
collagen-coated dishes.  Gentle shaking of the plated cells ensured that the cells were 
plated evenly.  The cells were fed 2 days post plating with complete growth medium. 
2.3 Culturing of Primary Mouse Mammary Epithelial Cells 
Primary mouse mammary epithelial cells were cultured in Hams F12 medium 
supplemented with 10% FBS, 50 μg/ml gentamycin, 100 U/ml penicillin, 100 μg/ml 
streptomycin, 0.25 μgml fungizome, 10 ng/ml EGF, 5 μg/ml insulin and 1 μg/ml 
hydrocortisone to make the complete growth medium. All cultures were maintained 
at 37oC in a 5% CO2 atmosphere.   
The supplementary growth factors in the growth medium for culturing primary 
mammary epithelial cells have been used for over 30 years (Emerman et al., 1981).  
In the culture medium, the insulin is present as a survival factor (Farrelly et al., 
1999) whereas EGF stimulates cell proliferation and also acts to promote cell survival 
(Fleming et al., 2006).  Hydrocortisone facilitates the formation of tight junctions and 
assists in the development of the cellular polarity (Nguyen and Neville, 1998).  
Gentamycin, penicillin, streptomycin and fungizone prevent bacterial and fungal 
growth in the culture medium (Aggeler et al., 1991). 
2.4 Passaging of Primary Mouse Mammary Epithelial Cells 
Primary epithelial cells to be passaged were cultured in monolayer on 145 mm 
collagen coated dishes for 3 days in complete growth medium.  The cells were then 
washed in   10 ml HBSS/EDTA (HE) (HBSS calcium-free medium containing 4.17 mM 
NaHCO3,  5 mM EDTA and a few drops 0.5% phenol red, preheated to 37oC) and 
incubated in a further 10 ml HE (37oC for 5 minutes).  The HE was aspirated off, and 
the cells incubated in 3 ml 1x trypsin/EDTA solution (Cambrex) at 37oC, until the cells 
detached from the dish (typically 3 minutes).  Trypsin activity was quenched by 
adding equivalent volume of complete medium, and the cells were collected by 
centrifugation at 375g for 4 min. Cells were resuspended in desired volume of media 
and replated. 
For every experiment described in this thesis using primary MECs, the data was 
collected from at least three independent preparations of MEC’s and experiments 
were often performed in duplicate or triplicate in each prep. 
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3.0 Additional Methods 
3.1 Statistical Analysis 
The majority of the statistical tests to determine significance of results were using 
the students t-test, where only two parameters were being compared i.e. Control and 
4OHT (β1 null) MECs in Chapter 3.  For the experiments where an analysis of 
variance analysis (ANOVA) was required, it was a one-way ANOVA and a Bonferonnis 
post-hoc test was carried out.  To use this test, the data is assumed to have a 
Gaussian (normal) distribution; however, it was not always possible to determine this 
for certain.  A Bartletts test could not be used to verify a normal distribution, as the 
sample size was too small in my experiments.  Therefore the analysis was repeated 
using a non-parametric test, which does not assume a normal distribution of the 
data.  The Kruskal-Wallis test was used with a Duns post hoc test and this showed 
the same significance result as the original ANOVA test, suggesting that my data has 
a Gaussian distribution.  
3.2 Determining Concentration of Growth Factors (Chapter 2) 
The concentrations of the growth factors (FGF-2, Wnt3a and RANKL) used in Chapter 
2 were determined by the use of a dose-response curve (see Figure 2A for FGF-2) or 
using concentrations determined to have a physiological effect in the literature. 
3.3 Immunofluorescence Controls 
Negative controls i.e. no primary antibody were routinely performed for all 
immunofluoresence staining experiments.  They were checked on the microscope 
first, before proceeding with the analysis of actual experiments with different 
antibodies.  Negative controls were scrutinised particularly carefully when a new 
antibody was being used.  Figure 3A shows three such negative control experiments 
with different combinations of commonly used secondary antibodies on primary MECs 
(Figure 3A).  It shows the lack of staining in the absence of primary antibody and 
ensures that all staining shown in the rest of this thesis was down to specific staining 
of primary antibodies. 
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Figure A2: Dose-response experiment for effects of FGF-2 on proliferation in 
primary MECs 
a) BrdU analysis of primary MECs treated with varying amounts of FGF-2 to 
determine the effects on proliferation. b) Quantification of percentage of BrdU 
positive cells in primary MECs treated with varying concentrations of FGF-2. 
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Figure A3: Negative controls for Immunofluorescence experiments 
Immunofluorescence negative controls for commonly used secondary antibodies a) 
Anti-rabbit Alexa488 and anti-rat Alexa594 secondary antibodies only used for 
experiments using FAK and β1 integrin. b) Anti-rat Alexa488 and anti-mouse 
Alexa594 secondary antibodies only used for experiments using paxillin and β1 
integrin. c) Anti-mouse Alexa488 and anti-rabbit Alexa594 secondary antibodies only 
used for experiments using fibronectin and phospho-ERK.  
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Alignment map for Taqman Gene expression assay probe Mm01253233_m1 for β1 
integrin from Applied Biosystems 
Chosen probe highlighted by green box  
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Alignment map for for Taqman Gene expression assay probe Mm00443972_m1 for 
β3-integrin from Applied Biosystems 
Chosen probe highlighted in green box 
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Alignment map for for Taqman Gene expression assay probe Mm01266844_m1 for 
β4 integrin from Applied Biosystems 
Chosen probe highlighted in green box 
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Alignment map for for Taqman Gene expression assay probe Mm00439825_m1 for 
β5 integrin from Applied Biosystems 
Chosen probe highlighted in green box 
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Alignment map for for Taqman Gene expression assay probe Mm00445326_m1 for 
β6 integrin from Applied Biosystems 
Chosen probe highlighted in green box 
 
